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Colon cancer is the second deadliest cancer, affecting the quality of life in older patients. 
Prognosis is useful in developing an informed disease management strategy, which can improve 
mortality as well as patient comfort. The morphometric assessment provides diagnosis, grade, 
and stage information. However, it is subjective, requires multi-step sample processing, and 
annotations by pathologists. In addition, morphometric techniques offer minimal molecular 
information that can be crucial in determining prognosis. 
The interaction of the tumor with its surrounding stroma, comprised of several biomolecular 
factors and cells is a critical determinant of the behavior of the disease. To evaluate this interaction 
objectively, we need biomolecular profiling in a spatially specific context. In this work, we achieved 
this by analyzing tissue microarrays using infrared spectroscopic imaging. We developed 
supervised classification algorithms that were used to reliably segment colon tissue into 
histological components, including differentiation of normal and desmoplastic stroma. Thus, 
infrared spectroscopic imaging enabled us to map the stromal changes around the tumor. This 
supervised classification achieved >0.90 area under the curve of the receiver operating 
characteristic curve for pixel level classification.  
Using these maps, we sought to define evaluation criteria to assess the segmented colon images 
to determine prognosis. We measured the interaction of tumor with the surrounding stroma 
containing activated fibroblast in the form of mathematical functions that took into account the 
structure of tumor and the prevalence of reactive stroma. Using these functions, we found that 
the interaction effect of large tumor size in the presence of a high density of activated fibroblasts 
provided patients with worse outcome. The overall 6-year probability of survival in patient groups 
that were classified as “low-risk” was 0.73 whereas in patients that were “high-risk” was 0.54 at 
p-value <0.0003. Remarkably, the risk score defined in this work was independent of patient risk 
assessed by stage and grade of the tumor. Thus, objective evaluation of prognosis, which adds 
to the current clinical regimen, was achieved by a completely automated analysis of unstained 
patient tissue to determine the risk of 6-year death.   
In this work, we demonstrate that quantitative chemical imaging using infrared spectroscopic 
imaging is an effective method to measure tumor-tumor microenvironment interactions. As a top-
down systems pathology approach, our work integrated morphometry based spatial constraints 
and biochemistry based stromal changes to identify markers that gave us mechanistic insights 
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into the tumor behavior. Our work shows that while the tumor microenvironment changes are 
prognostic, an interaction model that takes into account both the extent of microenvironment 
modifications, as well as the tumor morphology, is a better predictor of prognosis. Finally, we also 
developed automated tumor grade determination using deep learning based infrared image 
analysis. Thus, the computational models developed in this work provide an objective, 
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CHAPTER 1: INTRODUCTION  
Motivation and impact 
Colon and rectal cancer are the second in estimated deaths due to cancer after lung and bronchus 
cancer[1]. Approximately 4.2 percent of men and women will be diagnosed with this disease at 
some point during their lifetime, and only about 65% will survive five years after detection[1]. The 
current clinical needs in colon carcinoma diagnosis and management can be summarized as 
follows: 
(1) Need for objective evaluation: Although histopathology is the current gold standard for 
colon cancer diagnosis and prognosis, it suffers from numerous drawbacks such as 
experimental variations, limited information content and inter-observer variability[2,3] 
resulting in up to 11.8% errors in cancer diagnosis[4]. In addition, several studies have 
reported a lack of concordance in determining tumor grade[5,6] and interobserver 
variability in the assessment of dysplasia[2,3]. Therefore, methods that can perform 
objective evaluation without intensive tissue processing are needed.   
(2) Quantification of tumor-microenvironment associated prognosis: Unlike breast cancer 
where hormone receptor status stratifies outcome and determines therapy options[7], 
reliable prognostic and response predictive markers are not in clinical use in colon cancer. 
Carcinoembryonic antigen (CEA) is used to monitor patients post-surgery but is only 
useful for the early detection of metastasis in stage II and stage III cancers[8,9]. It has 
been demonstrated that the tumor microenvironment plays a vital role in determining 
tumor behavior[10]. Specifically, in colon cancer, studies have shown that the 
desmoplastic reaction around the tumor has prognostic significance[11,12]. Despite the 
reports, using the desmoplastic response as a prognostic marker is not clinically feasible 
because the evaluation criteria are subjective, and varies with pathologists. In addition, 
this model does not take into account the spatial interaction of the tumor with its 
microenvironment. Therefore, there is a need to develop robust models to quantify tumor-
tumor microenvironment interaction and assess their utility in determining prognosis.  
(3) Protocols for automation: Automation is possible using deep learning based machine 
vision applications in the assessment of patient tissue. In a large number of samples, 
determining the presence or absence of tumor is straightforward but still requires 
pathologists’ time and effort. Thus, there is a need to develop automated tools which can 
cut down on the workload of pathologists by removing apparent cases.  
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(4) Improving speed of assessment and in-surgery assistance: At the time of the surgery, if 
histopathological aid is needed, the tissue is snap frozen, sectioned, stained and a 
pathologist assesses the sample. There is potential to improve this pipeline by performing 
rapid tissue assessment right on the surgery bench without the need for tissue processing. 
Thus, there is a need to develop and evaluate high-speed imaging modalities capable of 
performing the stainless assessment.  
Colorectal cancer prevalence and clinical assessment 
Colorectal cancer is the cancer of the colon or rectum. Adenocarcinoma is the most common 
colorectal cancer subtype, accounting for about 90% of the colorectal cancer cases, although 
other types of cancers such as lymphoma and squamous cell carcinoma can also originate from 
the colon. Adenocarcinoma originates from epithelial tissue that has a glandular origin (adeno- 
meaning gland). In colon cancer, the disease arises from the epithelial cells lining the colon or 
rectum (colon crypts), invades the thin layer of muscle in the gastrointestinal tract known as 
muscularis mucosae, followed by invasion in the submucosa and eventually muscularis propria 
(figure 1.1). In cases of colorectal cancer, when submucosal invasion takes place, the tumor is 
rendered invasive (pT1)[13]. 
The initial diagnosis of colon cancer is made by colonoscopy, following which surgical excision or 
biopsy can be performed.  Colonoscopy is a versatile method to determine the tumor location. 
Once a suspicious mass is sampled, pathological diagnosis can be made by examining the tissue 
after histological stains. The most common stain used for tissue examination is hematoxylin and 
eosin (H&E). Using the stained tissue, pathologists confirm if a malignant tumor is present, and 
the depth of invasion. In the case of surgical resection, multiple regional lymph nodes are 
examined to determine if cancer has spread to the lymph nodes. Based on the structure and 
organization of the tumor and the nuclei, a tumor grade can also be assigned, which has been 
shown to be a stage-independent prognostic factor[14] (figure 1.2).  
While anatomic pathology utilizes morphometric information to perform diagnosis, it is limited by 
molecular information content, and often does not provide a functional basis for the 
abnormality[15] (figure 1.3a). Molecular information can be supplemented by the use of 




Chemical imaging as a tool for colon cancer assessment  
Chemical imaging using Fourier transform infrared (FT-IR) spectroscopic imaging offers spatially 
specific molecular analysis of samples, without the need for stains or dyes (figure 1.3c). Infrared 
imaging can be used for comprehensive molecular assessment of the tissue and for determining 
prognosis. This approach is timely to use given the recent advancements in high definition IR 
spectroscopic imaging coupled with machine learning to perform image analysis and prediction. 
In the following sections, we review the prior works that have studied colon tissues using chemical 
imaging.  
Biological basis of FT-IR spectra 
Prior works have demonstrated that there is a functional difference between a healthy colon and 
colon cancer that can be measured using chemical imaging. Early studies using FT-IR 
spectroscopic imaging have shown that the levels of cell metabolites decrease in polyp and colon 
cancer relative to normal tissue[16]. Further work on the analysis of adenomatous crypts showed 
that abnormal crypt proliferation could be identified by using FT-IR spectroscopic imaging. The 
abnormal crypts showed a lower absorbance of glycogens, phosphates and lipids at the bottom 
and middle portion of the crypt as compared to the top, whereas normal crypts had a higher overall 
absorbance at the middle[17,18].  In normal crypt, the cells had lower carbohydrate levels at the 
apex of the crypt, the levels of carbohydrates did not change much between middle and apex in 
abnormal crypts, showing that the cells in abnormal crypts retained their metabolism activity even 
at the top of the crypt. Metabolite levels have also been observed by collecting samples from 
intestinal mucosa as we move away from the tumor and it was found that there is a decrease of 
lipid and increase of proteins and nucleic acids in the regions close to tumors[19]. A similar 
increase in protein and nucleic acids has been observed elsewhere[20]. Several studies have 
attempted to utilize these differences to segment colon tissue using unsupervised clustering 
approaches (figure 1.4a). The unsupervised classification algorithms perform well on individual 
samples, and demonstrate the power of infrared spectroscopic imaging in distinguishing colon 
tissue histological components[21–25]. However, they fail when multiple patient samples are 
used, given that patient heterogeneity can have strong effects on the signal[26].  
FT-IR spectroscopic imaging to analyze features not observable through traditional techniques 
Besides conventional FT-IR spectroscopic imaging studies investigating the biochemical signal 
distribution and attempting to reproduce classical histology[27], FT-IR spectroscopic imaging has 
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also been employed successfully to identify features that are not detectable with conventional 
H&E staining. For example, tumor budding and tumor stroma association can be studied using 
FT-IR spectroscopic imaging;  both of these features are either unidentifiable through traditional 
histological staining or require high power magnification[28].  
Colonic carcinogenesis has known variations in mucin-type glycoproteins.  MUC1 mucin is 
increased in colon cancer, and correlates with a worse prognosis, whereas the expression of 
MUC2  is generally decreased in adenocarcinoma[29].  Multiple studies have attempted to 
analyze this variation using infrared spectroscopy[30–34].  One study in particular identified that 
the mucin spectral features did not vary in normal and adenocarcinoma tissues but there was a 
difference in the surface percentages of mucin which can allow us to differentiate between these 
two tissue types (figure 1.4b).[34]  
Tumor heterogeneity is studied widely in terms of cell surface receptors, proliferation capabilities 
and angiogenic potential[35,36]. These biological variations are not observable using H&E stain. 
In work on xenograft colon carcinoma models, IR spectroscopic imaging was shown to be useful 
in identifying three distinct spectral clusters, one of which was associated with mucin-producing 
cells[37]. Thus, it is likely that IR imaging is more effective in documenting the tumor heterogeneity 
as compared to the H&E staining.  
Clinical applications of FT-IR 
When colon tissue is examined under visible light, specialists look for raised lesions called polyps. 
These can be either benign or malignant, but this distinction can only be made by looking at the 
biopsy. Argov et al.[38] attempted to characterize premalignant polyps using IR spectroscopic 
imaging and compare them with normal and colon cancer cases. The authors used multilayer 
perception artificial neural networks to classify the tissue and noted that spectral differences 
between polyp and malignant cases were not significant. Phosphate stretching bands were able 
to differentiate normal from both polyp and malignant cases but failed to separate pre-malignant 
polyp from cancerous cells. Instead, it was shown that the glycogen peaks at 1026 cm-1 and 1154 
cm-1 performed better as features to distinguish hyperplasia from dysplasia [39].  
Identifying dysplastic polyps through histopathology is a tedious process, involving patient 
sedation and additional costs. Keeping this in mind, Mackanos et al.[39] developed FT-IR 
spectroscopy to assist endoscopy using silver halide optical fiber in ATR configuration. The 
authors used freshly excised specimens to evaluate the potential of infrared spectroscopy to 
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identify dysplastic mucosa. The samples were blown with cold air for five minutes to remove water 
interference.  Using this model, the authors found subtle differences in the absorption spectra 
among normal, hyperplasia and dysplasia in the fingerprint region using partial least squares 
discriminant analysis, reporting a specificity of 92% at 96% sensitivity and an AUC value of 0.953. 
The authors pointed out that using a classification algorithm that is more efficient regarding 
calibration transfer between the optical fiber instruments is needed, and can be combined with an 
endoscope-compatible optical fiber to distinguish premalignant colonic mucosa; producing a 
significant leap in in situ infrared imaging. Other groups have reported a series of experiments 
starting from in vitro studies to using ATR based fiber optic probe for in vivo FT-IR spectroscopy 
and have reported agreements between in vivo and in vitro data and the observations being 
consistent with biopsy results[40].  ATR-FTIR based study, other works have reported 
identification of colonic inflammation[41] as well as differentiation of colon cancer from colitis using 
[42]. One such setup is shown in figure 1.4c.   
Together, these studies show that FT-IR spectroscopy can produce results equivalent and 
superior to traditional staining techniques, giving additional biomolecular information and has 
potential to capture metastasis and prognosis associated features. Clinical implementation of this 
technique is possible with faster imaging systems such as quantum cascade lasers[43–45] while 
optimized classification algorithms can produce results at clinically relevant time scales. This is 
specially needed for colon cancer analysis, which does not have clinically prevalent prognostic 
markers. In addition, colon tissue is accessible with probe based instruments, and demonstrations 
that infrared spectroscopic imaging in situ is compatible with endoscope further strengthen the 
motivation to develop advanced analysis techniques using chemical imaging to probe colon 
tissue.  
In chapter 2, we describe methods to optimize IR data collection and analysis for cancer 
applications. In chapter 3, we discuss the importance of tumor-microenvironment based analysis 
in the systems pathology context. Chapters 4 describes our work in probing tumor-tumor 
microenvironment interactions by utilizing chemical imaging to determine patient prognosis. 
Finally in chapter 5, we describe approaches to speed up and automate colon cancer tissue 






Figure 1.1: A section of colon showing colon histology. The colon crypts consist of mature 
epithelium that produces mucin, along with stroma surrounding the cells known as lamina 
propria. A thin muscle layer called as muscularis mucosae is followed by submucosa 
comprised of large number of blood vessels, lose stroma and neural cells. A thicker 






Figure 1.2: Hematoxylin and eosin stained biopsy tissue can be used for diagnosis and 
determining tumor grade. The figure shows an H&E stained benign colon tissue in 
comparison to malignant tissues of different tumor grades. The low grade, or “well-
differentiated” colon cancer is the closest to normal colon tissue, with well defined glands 
and polar nuclei. Moderate grade tumors show some degree of gland formation, and the 
nuclei can be seen as losing polarity. In high grade or “poorly differentiated” carcinomas, 





Figure 1.3: Current methods to analyze colon tissue. (a) After surgical resection or biopsy, 
anatomic pathology can be used to determine the presence of tumor and tumor grade and 
stage. However, it has limited molecular information. (b) Molecular analysis using tools 
such as proteomics and genomics provide a wealth of molecular information, but do not 
provide a spatial context. (c) Chemical imaging using infrared spectroscopic imaging 
provides higher molecular resolution compared to anatomic pathology in a spatially 
specific context. Bands in the IR spectrum correspond to specific functional groups, and 




Figure 1.4: Development of computational tools and instrumentation using chemical 
imaging to diagnose and analyze colon tissue samples. (a)1 Multiple unsupervised 
clustering approaches have segmented colon tissues using infrared spectroscopic 
imaging signals. (b) The surface percentage of spectroscopically distinct mucin can be 
used as a feature to separate normal colon tissues from adenocarcinoma samples (c) 2A 
flexible silver halide fiber can be used to collect infrared absorption spectra from freshly 
excised tissue, eliminating the need of extensive sample processing. 
  
                                               
1 Parts of figure 1.4 (a) and (b) adapted with permissions from Travo, Adrian, Olivier Piot, Rolf Wolthuis, Cyril Gobinet, Michel 
Manfait, Jacques Bara, Marie‐Elisabeth Forgue‐Lafitte, and Pierre Jeannesson. "IR spectral imaging of secreted mucus: a promising 
new tool for the histopathological recognition of human colonic adenocarcinomas." Histopathology 56, no. 7 (2010): 921-931. 
2 Parts of figure 1.4 (c) obtained with permission from Vinay K. Katukuri, John Hargrove, Sharon J. Miller, Kinan Rahal, John Y. Kao, 
Rolf Wolters, Ellen M. Zimmermann, and Thomas D. Wang, "Detection of colonic inflammation with Fourier transform infrared 
spectroscopy using a flexible silver halide fiber," Biomed. Opt. Express 1, 1014-1025 (2010). 
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CHAPTER 2: METHODS: CHEMICAL IMAGING AND DATA ANALYSIS FOR DIGITAL 
CANCER DIAGNOSIS3 
Abstract 
Fourier transform infrared (FTIR) spectroscopic imaging is an emerging microscopy modality for 
clinical histopathologic diagnoses as well as for biomedical research. Spectral data recorded in 
this modality are indicative of the underlying, spatially-resolved biochemical composition but need 
computerized algorithms to digitally recognize and transform this information to a diagnostic tool 
to identify cancer or other physiologic conditions. Statistical pattern recognition forms the 
backbone of these recognition protocols and can be used for highly accurate in results. Aided by 
biochemical correlations with normal and diseased states and the power of modern computer-
aided pattern recognition, this approach is capable of combating many standing questions of 
traditional histology based diagnosis models. For example, a simple diagnostic test can be 
developed to determine cell types in tissue. As a more advanced application, IR spectral data can 
be integrated with patient information to predict risk of cancer, providing a potential road to 
precision medicine and personalized care in cancer. The IR imaging approach can be 
implemented to complement conventional diagnoses, as the samples remain unperturbed and 
are not destroyed. Despite high potential and utility of this approach clinical implementation has 
not yet been achieved due to practical hurdles like speed of data acquisition and lack of optimized 
computational procedures for extracting clinically actionable information rapidly. The latter 
problem has been addressed by developing highly efficient ways to process IR imaging data but 
remains one that has considerable scope for progress. Here we summarize the major issues and 
provide practical considerations in implementing a modified Bayesian classification protocol for 
digital molecular pathology. We hope to familiarize readers with analysis methods in IR imaging 
data and enable researchers to develop methods that can lead to the use of this promising 
technique for digital diagnosis of cancer.  
Introduction 
Infrared (IR) spectroscopic imaging is a promising avenue for computerized disease 
diagnosis,[46–52] especially for cancer[18,46,47,53–62] and a multitude of other diseases[63]. It 
is of particular relevance for recognizing features within solid tissues in which a variety of cell 
types and disease states may be present. Utilizing the tandem spatial and molecular information 
                                               
3 Reprinted with permission, from Tiwari, Saumya, and Rohit Bhargava. "Extracting knowledge from chemical imaging data using 
computational algorithms for digital cancer diagnosis." The Yale journal of biology and medicine 88.2 (2015): 131-143. 
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acquired using a combination of IR spectroscopy and optical microscopy, this technique relies on 
using the biochemical composition as a means to automate disease identification. In IR imaging, 
no stains are used. Instead, the chemical composition of the material is recorded via a local 
spectrum and computer algorithms are used to relate the data to underlying physiologic 
conditions. Since only light is used to record the necessary data, the technology is entirely non-
perturbing to a prepared sample. The overall idea of using IR imaging for biological applications 
is shown in figure 2.1. This approach is orthogonal to the current practice in histopathology, which 
requires staining to visualize tissue morphology as well as requires intensive human involvement 
to recognize and categorize morphological features that are indicative of disease. The IR-based 
approach strongly relies on sophistication and utility of the numerical methods used. The focus of 
this article is to describe and highlight the salient features of numerical methods used in IR 
imaging. 
IR imaging to address current cancer pathology needs 
At present, the gold standard to identify many types of cancers is to perform a biopsy. The poorly 
quantitative procedures following the biopsy and staining are semi-automated at best, and still 
suffer from user introduced variability[64,65]. This not only introduces subjectivity in 
examination[66], but also increases load on pathologist which they could otherwise devote to 
more complicated cases. Misclassification of biopsies during screening and diagnosis may lead 
to overtreatment or undertreatment, posing significant concerns for patients. A recently published 
report, for example,[67] evaluated the agreement among 115 pathologists who interpreted a total 
of 240 cases of breast biopsy samples which was compared with the consensus derived reference 
diagnoses from three expert pathologists. The researchers found out that the overall agreement 
between the participating pathologists’ interpretations with the reference was 75.3%.  Alarming 
underinterpretations were found in Ductal Carcinoma in situ (DCIS) cases (13%) and atypia cases 
(35%). Considering that DCIS accounts for 15% to 25% of the newly diagnosed breast cancer 
cases currently in the USA[68] and identification of atypical cells often requires further rounds of 
biopsy to establish aggressiveness of possible tumor, large numbers of patients could be affected 
every year based on whether or not second opinion is obtained. In another recent study[69], the 
researchers consulted 252 pathologists to assess the policy of obtaining second opinion on a 
variety of specimens. Their response indicated that mandatory second opinion was only required 
in 56% of the laboratories when DCIS was diagnosed and in 36% laboratories when atypical 
ductal hyperplasia was observed. In many cases, a third opinion was required to resolve the 
differences between the first and second opinions. Studies like these and others[70–72] clearly 
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go on to show that there are a lot of cases in breast cancer that are affected by confusions in 
classification of type and aggressiveness of tumor, and that current pathology practice is in need 
of better tools to aid diagnoses.  
Multiple computer aided detection systems have been used in past to assist the pathologists and 
help them reduce occurrences of false positives and false negatives[73]. In current practice, the 
computer aided detection systems that rely on pattern recognition software used by radiologists 
can be considered semi-automated in that some degree of human interaction is still needed 
before final decision is given. In that sense, detection systems are different from diagnosis 
systems which are capable of rendering a decision based on a consideration of variety of factors 
like mass of tumor, biochemical data from biopsy and patient characteristics like breast density 
and age. These systems thus require integration of two major fields; computation and imaging. In 
terms of imaging for diagnostic cancer pathology, the foremost requirement is the ability to 
generate contrast between diseased regions and healthy regions. Traditionally, chemical and 
immunohistochemical stains have been used to produce this contrast that is, in a second step, 
referred to pathologist for evaluation. The second step is now increasingly involving the use of 
computers to manage images and assist with decisions using numerical indices or other image 
analysis techniques. However, there are emerging alternatives to this long standing 
instrumentation. For example, microscopic contrast can also be produced optically using Raman 
imaging or IR spectroscopy – two strongly emerging modalities, which also place new 
requirements and provide new opportunities for the associated computational methods. IR 
spectroscopic imaging has some distinct advantages over other contrast producing modalities. 
First, it requires minimal sample preparation. Freshly taken tissue can be snap frozen and imaged 
without further aids. This greatly reduces variations during experimental stages making the 
procedure standardized and efficient. It can as easily be applied to archival samples. Second, IR 
imaging does not require contrast agents but utilizes the inherent biochemical contrast in the 
tissues for differentiation of diseased state. Third, the chemical changes recorded by infrared 
spectroscopy across the tissue are capable of giving the same information as achieved by 
histological stains[74]. In addition to it, since the information is computer generated, they provide 
greater contrast and statistical confidence, in turn enabling identification of problematic areas 
easier. A recently published report[27] showed that a single IR spectral image could reproduce 
staining patterns of multiple stains such as Hematoxylin and Eosin (H&E), Masson’s trichrome 
stain, cytokeratin stain, smooth muscle alpha actin, and vimentin (figure 2.2). This could allow the 
researchers to analyze the samples through multiple stains, without putting in additional time, 




Along with reproducing classical stains with great accuracy, data generated by IR imaging is 
highly amenable to computational analysis and pattern recognition algorithms are easily 
integrated for obtaining decisive reports. Currently, a major goal of the typical studies performed 
using IR imaging on tissue samples is to build classification systems that color code IR images to 
differentiate between different types of cellular and acellular components, much like H&E and IHC 
stains. Classes such as epithelium, endothelium, stroma and muscle have been identified[75,76] 
and more cellular and acellular components are being added through current research. Although 
this approach provides high contrast images with minimal sample preparation for the use of 
trained pathologists, in order to truly utilize the potential of IR imaging for cancer diagnosis, further 
computational prediction needs to be implemented. A recent report,[77] for example, attempted 
to precisely predict recurrence of prostate cancer using IR imaging data and showed that this 
approach outperformed both Kattan nomogram and CAPRA-S scores for outcome predictions. 
Together, emerging studies are opening new avenues for utilization of IR based models for cancer 
diagnosis and therapy by combining imaging, molecular detection and computational cancer 
prediction to augment human decision-making. Owing to the practical requirements of speed of 
imaging and data acquisition and processing, no automated diagnosis systems have been 
clinically implemented till now; nevertheless, fast progress is being made to achieve this goal and 
will be discussed briefly in later sections. We first provide an overview of the methods, highlighting 
special considerations and challenges that use this data and lead to decision-making in cancer 
research and care. 
Classification models 
A biological sample characteristically consists of many cell populations and extracellular matrix 
elements. All of these elements serve a function in the sample, and imbalance in the chemical 
composition and morphology of these can be a cause or an effect of a disease. Thus, these 
cellular and acellular components of tissue are carefully scrutinized by pathologists to obtain 
information about the ailment. We refer to all such functional elements as histological classes or 
simply classes. The idea underlying the use of IR spectroscopy for disease detection is that each 
such class will have a different biochemical composition and therefore unique spectral signature 
in IR absorbance spectra. Since digital spectral data is available for each pixel from the sample, 
we can employ pattern recognition algorithms to utilize these differences for recognition of 
classes. Various classification approaches have been used in past to identify classes, termed as 
classification. Multiple studies have been performed for the analysis of data using various 
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classification algorithms, and are summarized here. For an in-depth theory on classification 
methods pertaining to biomedical imaging, the readers are directed to these references[76,78,79]. 
Typically, all methods can be classified into supervised or unsupervised methods – both of which 
are described briefly below. Subsequently, we focus here on describing the typical process of 
obtaining data, computational pipeline and typical results obtained. We illustrate the entire 
process with representative examples to enable the reader to grasp the essential steps of 
extracting information from IR images.  
(a) Unsupervised Classification 
The premise of unsupervised classification is that no prior information (for example, spectral 
characteristics of the classes) is fed to the method for classification. Hence, distinction between 
classes is often a problem of finding clusters in which intra-cluster variation is smaller than inter-
cluster variation. Unsupervised clustering approach has been applied previously to investigate 
tissue samples[80–82]. Since nothing is assumed known about the data classes, unsupervised 
processes can involve data reduction using the variance before applying a classification 
procedure. Such a methodology has been applied to classify IR imaging data from cervical cancer 
[83];  Principal Component Analysis (PCA) for data reduction followed by K means clustering was 
used elsewhere for classification of IR data[57]. Although unsupervised approaches work for 
exploratory analysis, they have been found to be computationally taxing and unable to 
differentiate between inter-class and intra-class variations, often necessitating the use of 
supervised classification algorithms[30,31]. In our opinion, the utility of these methods for IR 
imaging lies more in discovery rather than consistent knowledge extraction. 
(b) Supervised classification 
In supervised classification, prior information about the location and spectral properties of the 
classes is given to the classifier. Supervised algorithms such as discriminant analysis[47,84–86], 
neural network analysis[30,38,61,87,88] and Bayesian methods-based classification[42,75] have 
been used to classify tissue into various cellular and disease states. Underlying all these methods 
is the fundamental property of Bayes’ theorem, indicating that known patterns provide a statistical 
probability for identification of each class. Methods based on this property and its application for 
biological specimens has been discussed elsewhere[75]. Here we discuss the practical 
considerations for its implementation; in order to facilitate understanding and ease of use among 




Image collection and pre-processing 
Collecting a good quality image is the first step of any IR classification experiment. Often, this 
facet is overlooked. Good quality data reduces complexity of the methods and can provide faster 
as well as more accurate results. Multiple factors such as choice of substrate signal to noise ratio 
(SNR), spatial and spectral resolutions, and presence of contaminants like paraffin residue can 
affect the overall classification accuracy. In this section we will discuss methods employed to 
collect good quality data and prepare the data for classification. 
Substrates 
IR spectroscopic imaging data can be collected in both transmission and reflection mode. IR 
transparent substrates, such as calcium fluoride (CaF2) and barium fluoride (BaF2) salt crystals 
are excellent substrates since they achieve greater than 95% transmission in mid IR region. An 
overview of properties and uses of CaF2 and BaF2 crystals can be found in reference [89]. 
Specifically for imaging biological samples, BaF2 is preferable since transmittance of CaF2 cuts 
off at about 1000cm-1 and analysis at lower wavenumber (longer wavelengths) is not possible. 
BaF2 is more prone to damage, however, due to higher water solubility compared to that of 
CaF2[90], making its handling and maintenance slightly more difficult but not substantially different 
compared to standard glass slides. Once a sample is placed on these crystals, imaging is rather 
simple. Using a microscope objective-condenser setup, light simply passes through the substrate 
and the sample in a “transmission” mode. The major problem with either substrate is cost –which 
can run from tens to hundreds of dollars. Due to high cost of these substrates and higher 
maintenance requirements compared to standard glass slides, many IR studies now utilize IR 
reflective substrates such as gold coated slides and Low-E slides (MirrIR, Kevley Technologies). 
Low-E slides, in particular have been very useful for IR imaging owing to their ability to transmit 
visible light and reflect infrared light. Thus, imaging is often conducted in the transflection mode 
with these substrates. In the transflection mode, light is incident upon the sample, passes through 
it, is reflected from the sample-substrate interface and re-transmitted through the sample. Due to 
the sample typically being of a thickness that is the same order as the wavelength of light, passing 
through the sample twice results in distortions in the spectrum[91,92] compared to the 
transmission case. However, some pre-processing steps have been reported that can effectively 
encounter most of the side-effects of transflection mode and are discussed in section 2.5. With 
emerging methods and more flexibility in terms of cost and maintenance[93] Low-E slides are 
attractive options to carry forward IR based detection technologies to everyday use in clinics.  
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Signal to noise ratio 
In IR imaging, the spectral signal to noise ratio (SNR) is the primary measure of the quality of 
data. It has been shown that high levels of noise in data negatively impact the classification 
accuracy[94]. Hence, SNR should be carefully considered in the design and use of any protocol. 
Modern infrared imaging instruments have combated the problem of low SNR quite well, and one 
can routinely obtain an SNR of greater than 200 on commercial instruments. There are multiple 
factors that can determine the SNR for data collected. For commonly used Focal Plane Array 
(FPA) detectors in IR imaging instruments, each element in detector records the spectrum from 
one pixel in the sample. As the number of co-additions is increased, the signal is recorded multiple 
number of times and averaged. This improves the SNR by the square root of the number of co-
additions. However, this also increases the time required for data acquisition almost linearly with 
the number of co-additions. Another option is to reduce spatial resolution (increase the size of the 
pixel at the sample plane) which can provide a higher SNR in smaller time due to a larger angle 
of light collected, but this may compromise identification of small sized cells in biological samples. 
An additional key factor while image collection is background spectrum. Every IR imaging 
experiment requires collection of background spectra that are used as a reference to obtain 
absorbance measurements. The number of co-additions for background spectrum should be 
much larger than the number of co-additions for the image in order to have minimal introduction 
of noise in signal from background[95]. Some limits on SNR are also imposed by the 
interferometer and other hardware, as well as multiple other factors such as spectral and spatial 
resolution, which is a result of complexities in the acquisition process. Some of the factors that 
affect SNR have been discussed in previous works[94–96]. Here we want to emphasize that the 
data quality in IR imaging is a balance between optimum SNR, optical configuration needed and 
the time required to achieve the desired SNR. One method we have not discussed thus far is the 
use of post-acquisition numerical processing techniques that can use statistical or other measures 
of noise reduction and lead to reduced noise in the images. The basic principle underlying these 
methods is to transform the data into a space that collapses all information into a minimum number 
of factors, for example, using principal components transform[97]. Fortunately, due to these 
computational noise reduction techniques (discussed in section 2.5) SNR is not a limiting factor 
for classification accuracy for many of the common tasks in spectroscopic imaging[94].  
Spatial and spectral resolution 
The main constituents of biological samples are the different types of cells that comprise the tissue 
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as well as the extracellular matrix (ECM) that holds tissue structures together. The size of 
eukaryotic cells can vary from about 5 to 30 microns. Sufficient spatial resolution is necessary to 
identify each cell type[98] and thus the instrumentation and experimental parameters must be 
carefully selected. Insufficient spatial resolution leads to the problem of mixed pixels, whereby, if 
the pixel is too large, it can have contribution from multiple cells, leading to greater confusion and 
low accuracy of classification[76]. Typically, pixel size used for IR microscopy had been 
approximately 5 µm x 5 µm. Pixel size in attenuated total reflectance (ATR) mode can be higher 
due to the use of a solid immersion lens[99–101]. A microscope equipped with transmission optics 
and ATR lenses can provide higher resolution depending on the solid immersion lens or ATR 
crystal material. For example, one commercial instrument provides a pixel size of 6.25 µm x 6.25 
µm in the transmission mode and 1.56 µm x 1.56 µm sized pixels in ATR mode using a 
Germanium lens (refractive index ~ 4). High definition IR imaging instruments typically seek to 
provide 1 µm x 1 µm. It should be noted that the pixel size is not the same as resolution. Resolution 
is still determined by the Rayleigh Criterion; for example, it is ~5 m for transmission mode 
imaging and 1 m for ATR imaging. A comparison of IR images taken at various pixel sizes for 
mammalian cells is shown in figure 2.3. As can be seen, high amide absorbance region of nucleus 
is much better resolved with high spatial resolution as compared to the low resolution transmission 
image. Effect of varying pixel size on classification is shown in figure 2.4(ii, iii) where 6.25 µm x 
6.25 µm pixel size data is compared to 25 µm x 25 µm pixel size data. H&E image with marked 
classes is shown for comparison (figure 2.4(i)). Higher pixel density via smaller pixel sizes 
provides IR images that are closer to histologic stain image, whereas more averaging to increase 
SNR and larger scanning time to acquire more pixels is required. The large pixel sizes result in 
overlapping of signals from different cell types and the ECM, reducing confidence in classification. 
A large pixel can reduce the scanning time greatly and provide high SNR. For most biological 
problems involving complex tissues, however, a high spatial resolution is oftentimes needed. An 
equally important factor for good classification is spectral resolution. For very coarse spectral 
resolution, the peaks begin to overlap, causing significant reduction in classification 
accuracy[102]. Typical IR imaging experiments utilize a spectral resolution of 2 cm-1 to 16 cm-1. 
For biological specimens, spectral resolution of 4 cm-1 to 8 cm-1 is able to differentiate most of the 
significant peaks and has been found to give good classification results in our experience.   
Paraffin removal 
Since most samples are typically paraffin embedded and sectioned before IR imaging, the 
sections need to be deparaffinised in order to remove spectral contributions from paraffin, typically 
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occurring as a set of peaks from 2800 cm-1 to 3000 cm-1 due to C-H stretching vibrational modes 
and a strong peak at 1462 cm-1 due to C-H bending modes[103].  Deparaffinization carried out 
either in Xylene[85],  Hexane washes of 16-24 hours with mild stirring or with octane for 4 
hours[104] have all shown to remove paraffin features from spectrum. Figure 2.4 compares 
classification results from a paraffinized sample (figure 2.4(iv)) and same sample after paraffin 
removal (figure 2.4(iii)) for same spatial resolution. A spectrum from sample before and after de-
paraffinization is shown in figure 2.5.  Even though we avoided using parts of the spectrum from 
paraffin affected regions from 2800 cm-1 to 3000 cm-1 and around 1462 cm-1, the classification 
was more accurate for deparaffinized sample than the paraffinized sample for same spatial and 
spectral resolution. Classification of samples imaged without deparaffinization can also work if 
appropriate corrections are performed[22]. Nevertheless, if paraffin retention is known or 
suspected, care should be taken to address any signals arising from paraffin while performing 
classification. 
Preprocessing 
Once IR images are acquired, minimal data processing is needed for performing classification. 
Based on the SNR, computational noise reduction methods such as those based on the Minimum 
Noise Fraction (MNF)[94] may be needed before classification can begin. This is a modification 
of principal components analysis whereby the ordering of eigenimages is performed in decreasing 
order of SNR, and high SNR eigneimages are chosen for analysis. Noise statistics are calculated 
form the image data. MNF transform creates three files, covariance statistics of the noise file, 
MNF statistics file and forward MNF transformed file which contains bands with descending 
eigenvalues. Based on the eigenvalues, the user can determine which bands contain data, and 
which bands have predominant noise. Typically, top 20-30 bands contain good quality data. 
Inverse MNF transformation is then applied on the forward MNF transformed file by taking high 
eigenvalue bands. Most commonly, this type of noise reduction is needed for ATR and high 
definition imaging data. Baseline correction of data is needed for comparing spectral features 
attributable to absorbance across classes and gives a good estimate of the differences before 
training can begin. A variety of baseline correction options are known but all essentially 
approximate the known non-absorbing regions to zero. In one approach, all points where 
theoretically zero absorption is expected are first identified. Then, a linear two point correction 
algorithm across peaks of interest is used. It should be noted that, in imaging, the baseline points 
are often held to the same for all spectra in the sample. To account for thickness variations in the 
sample or between samples, normalization with amide I peak (1650 cm-1-1656 cm-1 based on 
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location of peak) is often required. For biological tissues, this is the peak of highest absorbance 
and introduces the least decrease in SNR after normalization. 
Classification protocol 
The classification protocol followed here is based on modified Bayesian classification. The 
complex multistep method is explained through the flowchart shown in figure 2.6. We describe 
the major steps in the workflow and discuss possible pitfalls while building and deploying a 
classification protocol. 
Selection of training and validation set 
The goal of the classification protocol discussed here is to identify different types of cells and ECM 
elements called histological classes. The ultimate goal is to develop a computational algorithm 
that provides accurate recognition of classes in an unknown data set that can be encountered in 
practice. In the first step, the protocol needs to be developed and tested to perform optimally. To 
initiate this process, two separate data sets are selected – one is used for training and the other 
for independent validation. In some cases, the validation may come from the calibration data set 
itself. In such cases, one fraction of the data is selected for validation and the protocol is trained 
on the remainder. The fraction left off is changed and a number of iterations of the process are 
averaged to train and validate. This “leave-one-out” procedure can be used when the numbers of 
samples or diversity of the data set is limited but it is always ideal to have completely independent 
training and validation sets. It must be ensured that there is sufficient representation of all classes 
for getting satisfactory classification, and to retain sufficient diversity for assessment of accuracy 
in validation dataset. In this approach, study design is critical as the method cannot predict 
conditions it has not been trained on. The measures of success should also be carefully defined. 
We favor the use of the receiver operating characteristic (ROC) curve which includes an 
assessment of both sensitivity and specificity of the method. Other approaches may be to 
maximize detection of any class or disease state (e.g. cancer) at a specified error rate or to 
evaluate errors in a holistic manner such as with confusion matrices. Finally, a statistically 
significant number of samples must be used to validate the protocol. While the numbers of 
samples needed for a diagnostic test is well understood, the sample size needed for satisfactory 
calibration in the IR is an ongoing subject of study[76,105]. In the absence of other guidance, the 
standard approach is to calibrate, validate and calculate the ROC curves for the classifier in order 
to assess the accuracy. The errors in classification must additionally be carefully assessed. Based 




Depending on the size of the sample, an FTIR imaging data set can be very massive, ranging 
from a few hundred megabytes to hundreds of gigabytes. Each pixel in an IR image carries 
spectrum, which is usually recorded in the FT configuration across the entire bandwidth of the 
spectrometer but is usually truncated to reduce the size of the stored data to a smaller range, e.g. 
750 cm-1 to 4000 cm-1. However, not all spectral elements are useful for classification. For 
example, a region between 1900 cm-1 to 2500 cm-1 is biologically inactive and can be further 
removed if spectral corrections that depend on extensive refractive index measurements are not 
to be performed[106]. One approach to dealing with imaging data is the emergence of the so-
called discrete frequency IR imaging in which, using filters[107,108] or a tunable laser[43,109–
113], only a few frequencies of interest are collected. This approach will likely prove useful only 
after the calibration process. Hence, in general, the entire spectrum is acquired and needs to be 
handled for the calibration step. Data reduction discussed here simply suggests using data that 
gives qualitative and quantitative information about the sample and removing redundant data. 
While it is not necessary for single cell studies which do not require large computational power, 
biopsy sections and tumor micro arrays (of the order greater than 1 mm X 1mm in size) would 
need much computing time if raw spectrum is used without data reduction. Further, confounding 
information may become included unless a careful selection of informative spectral regions is 
used. We can utilize spectral features such as peak height ratios, peak area to height ratio, peak 
area to area ratio and peak center of gravity to differentiate among classes. These parameters 
are known as spectral metrics. Metrics are defined by an expert spectroscopist by observing the 
spectrum in tissue to identify exact peak locations. Many metrics have biological relevance, for 
example glycogen to phosphate ratio (1030 cm-1/1080 cm-1), but sometimes the physiological 
relevance is not intuitive. Even then, at this point all possible metrics that show differentiation 
among classes based on class spectrum should be considered. For every new imaging 
experiment, it is necessary to define the metric definitions anew, in order to account for spectral 
differences among classes and small differences in peak locations.   
Identification of classes 
Identification of classes is the major factor that can determine accuracy of classification. To feed 
class characteristics as prior information for supervised classification, one needs an accurate 
identification of pixels used for training. This is typically performed with the help of an expert 
pathologist, often guided by H&E stained images or immunohistochemical images of 
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corresponding sections. Typically, the practitioner marks regions corresponding to different 
classes by microscopic examination of H&E stained section. Correspondingly, regions in IR image 
are marked as regions of interest (ROI). H&E stained section can be a serial section or 
neighboring section to the section utilized for IR spectroscopy. A much preferable approach is to 
first obtain infrared images from the sample and then perform H&E staining on the same sample 
so that an exact match can be obtained. Once the classes are marked, non-biological pixels from 
class layers should be removed by setting an intensity threshold value for biologically active band 
such as amide I band (~1652cm-1) to a high enough value to remove both tissue-less regions as 
well as those with excessive distortions due to edge effects[114–117]. Subjectivity is the biggest 
issue in identification of classes and there have been multiple studies in past that show that the 
interpretation of H&E stain suffers from inter-observer variability, and can have a role in false 
positive and false negative results[64,65,118]. In absence of any absolute identification criteria at 
present, we rely on the opinion of pathologist for identification of classes. This adds a human error 
to the classification, and care is taken to mark the regions on IR image exactly same as the 
regions identified by the pathologist on the H&E image (considered “gold standard” [76]). This 
prevents addition of further error in prior information for classifier training which relies on manual 
identification and marking of classes in IR data. An alternative is to use immunohistochemical 
stains to identify cell types and overlay the IHC images with the IR images. However, IHC stains 
are not known to be reliable all the time and staining intensity may be open to interpretation 
requiring the use of sophisticated methods[119]. 
Evaluating metric distributions 
The distribution of values of metrics forms the basis on which the classifier identifies and learns 
the differences among classes. An example of histogram is shown in figure 2.7 that is the type of 
data to evaluate the use of metrics. Here, the number of pixels versus the value of metric 
parameter for each class is plotted. For large enough number of pixels for each class, the 
histograms are expected to follow a Normal distribution unless there are sub-classes within the 
data. Hence, the first check is to determine whether there may be more than one distribution in 
the pixels, which may cause an examination of the model used in turn. For N metric parameters, 
we obtain N histograms. This step is important in identifying metrics which can potentially be 
useful in differentiating between classes. When comparing between two classes, the overlap 
between the distributions is the critical parameter to evaluate. A small overlap in distributions 
implies that the values of metric parameters are sufficiently different and can be used to 
differentiate between the classes. The actual efficacy of metric parameter depends on the fraction 
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of overlap that the probability distribution functions of different classes have with each other (figure 
2.7). It must be noted that abundance also comes into consideration here. For a given pixel, the 
overlap in normalized histograms can be considered. However, the probability of the selected 
pixel belonging to any particular class also needs to be considered. This depends not only on the 
native distribution of classes in normal and diseased conditions but also on the sampling process 
(e.g. biopsy). For example, it is well known that there is significantly more epithelium in cancer 
and in the peripheral zone of the prostate. Hence, simple abundance probability can be 
augmented significantly by known characteristics of the disease, patients and procedures 
performed. Caution must be exercised, however, in making models that are too specific. While 
such models may perform at high accuracy, their robustness is likely to be compromised. The 
metric distribution, hence, must be evaluated in light of the model, the classification methods and 
on the desired accuracy. A metric parameter which can differentiate at least between two classes 
is considered useful for the purpose of classification. Since multiple such parameters can 
eventually be used in conjugation to separate all classes from each other, the set of metrics to be 
used and the order of their usage will be evaluated next.  Following this step, with appropriate 
user input in determining histogram limits, a probability distribution file is created that contains the 
prior information of the classes.  
Determination of metric order 
After determination of probability distribution for every class in our case, a Bayesian classifier, 
each metric can be considered as a rule that determines which class the pixel belongs to. 
Therefore, the classifier goes through a series of rules to come to a decision about the class, 
assigning a class value to the pixel after each step is executed. In this perspective, it becomes 
important to determine the most optimum order of metrics so that the end result is closest to the 
true histology. For this average errors for metrics are calculated and pairwise errors are arranged 
in increasing order. This order is optimized by classifying with reordered metric, calculating the 
area under the receiver operating characteristic (ROC) curve, and recalculating pairwise error if 
there is an increase in area under the ROC curve. It has been shown before that only a fraction 
of metrics are actually needed to achieve the highest accuracy in classification[75]. Thus, after 
the optimum metric order has been defined, metrics coming at the bottom of the order can be 
removed from classifier. Typically, this set of 15-25 metrics is identified based on the metric order 
and area under the ROC curve but an additional step in optimization can be performed by 





Validation of the classifier is performed on an independent data set by comparing the classifier 
with pathologist annotated IR data in the manner similar to calibration. ROC curves and confusion 
matrices are commonly used to assess the accuracy of classification. The ROC curve leads to 
two measures – the area under the curve (AUC) of the ROC curve and the [sensitivity, specificity] 
operating point of the classifier. The AUC is a “global” measure of the how accurate the designed 
protocol can be on an average. Comparisons of AUCs, statistical limits and ordering of different 
models based on the AUC are all operations that can be used to refine the classifier and gain 
further insight[120–122]. The operating point, i.e. [sensitivity, specificity] can be considered to be 
a local condition that determines a particular operation of a diagnostic test. For any selected 
protocol there will always be an operating point, which trades-off the specificity and sensitivity, 
but is implemented for the test. This is often determined by the problem and the tolerable error in 
the test. Sensitivity of greater than 70% at high specificity (90%) are generally considered 
satisfactory for biomedical detection systems, although a much higher sensitivity and specificity 
is often desirable for tasks such as disease diagnoses or recognition of particular cells. For 
example, in one study, among multiple breast cancer surveillance methods such as MRI, 
mammography, ultrasound and clinical breast examinations; the sensitivity ranged from 9.1% to 
77% and specificity ranged from 95.4% to 99.8%[123].  When using IR based staining for digital 
cancer diagnosis, it is desirable to have sensitivity and specificity reach close to 100%. This has 
been shown to be possible by various recent studies[124,125]. While ROC curves determine the 
specificity and sensitivity of classification, the confusion matrices give the investigator an idea of 
confusion between classes in classification and both should be used to evaluate the performance 
of the classifier. In validation studies, these matrices often point to systematic errors in the 
development of the classification protocol and must be examined carefully.  
Conclusions 
Automated computational classification is a very powerful technique to utilize IR spectroscopic 
imaging data. We emphasize that due to multiple steps required in image acquisition and 
classification protocols, careful considerations throughout are needed to assure successful 
development of assays. Often, the process of development of a classifier is not linear and careful 
analysis and examination at each step is needed to ensure that the protocol is both accurate and 
robust. The theory and practice of Bayesian classification is well developed for infrared imaging 
data[75,76]. The protocols for image acquisition have also been described in detail in the 
past[102,126–128]. However, practical considerations while performing classification that can 
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greatly affect the classification accuracy have not been recorded in infrared imaging literature. 
Through this chapter, with illustrative examples, we have attempted to provide an introduction 
and a practical guide to considerations in the development of a specific classification protocol. 
Many of these considerations can be adapted for similar classification procedures, and we do 
hope that this article would enable and encourage the readers to familiarize themselves with 








Figure 2.1: Overview of the use of IR imaging for biological analyses.4  
                                               
4 Adapted with permission from Bhargava R. Towards a practical Fourier transform infrared chemical imaging protocol for cancer 




Figure 2.2: Molecular imaging (three sample panel on the left) can be reproduced by 
chemical imaging (right panel). In addition to H&E stained images (a), we extend the 
concept of stainless staining to molecularly specific stains, including (b) Masson’s 
trichrome stain (collagen and keratin fibers) (b) high molecular weight (HMW) cytokeratin 
(epithelial-type cell), (c) smooth muscle alpha actin (myo-like cell) and (d) vimentin 
(fibroblast-like cell). Each spot is 1.4 mm in diameter.5  
 
                                               
5 Adapted with permission from Mayerich D, Walsh MJ, Kadjacsy-Balla A, Ray PS, Hewitt SM, Bhargava R. Stain-less staining for 
computed histopathology. TECHNOLOGY 2015:1–5. doi:10.1142/S2339547815200010.World Scientific Publishing Co./Imperial 





Figure 2.3: Images of eukaryotic cell at varying resolutions; (a) ATR mode, pixel size 
1.56µm x 1.56µm; (b) Transflection mode 74X, pixel size 1.1µm x 1.1µm; (c) Transmission 
mode 14X, pixel size 6.25µm x 6.25µm. All images are at amide I band (1652 cm-1) 
 
 
Figure 2.4: Factors affecting classification; (i) H&E image with marked regions, I: Infiltrate, 
F: Fibrosis, N: Normal tissue; (ii) Classified image pixel size 6.25µm x 6.25µm 
(deparaffinized); (iii) Classified image pixel size 25µm x 25µm (deparaffinized); (iv) 
Classified image pixel size 25µm x 25µm (paraffinized) 
 










Figure 2.7: Histograms for metric evaluation; (a) An example of good metric (b) An example 
of metric that will have errors in classification when the metric value lies in the overlapping 




CHAPTER 3: QUANTITATIVE CHEMICAL IMAGING AS A TOP-DOWN SYSTEMS 
PATHOLOGY APPROACH6 
Abstract 
Cancer is a complex set of diseases, presently characterized by the primary site of origin and 
expression of biomarkers. The diagnostic gold standard, and for much of research, is the tissue 
structure and organization in microscopy images. Although histopathology of tumors provides 
necessary information for diagnosis, it is not predictive of therapy response. As a top-down 
systems pathology approach, the goal of quantitative chemical imaging is to develop 
computational models to observe, quantify, and validate our understanding of cancer progression. 
Mathematical models, as well as machine learning approaches, have previously been utilized to 
predict the tumor response, but comprehensive spatial and biochemical characterization of the 
tumor is lacking. This gap can be filled by a spatially specific biochemical analysis of tissue using 
chemical imaging. Here we discuss some fundamental concepts of systems pathology in the 
context of model developments involving chemical imaging.   
Background 
Pathology refers to the study of diseases. As an essential element of patient care, pathology is 
used to diagnose as well as prevent diseases. There are two sub-disciplines within pathology, 
clinical pathology, which is the analysis of fluid samples such as blood and urine targeting specific 
analytes and pathogens; and anatomic pathology, pertaining to the microscopic examination of 
solid samples such as tissue sections for diagnosis of diseases[129]. Histopathology is the gold 
standard for clinical diagnosis of cancer where morphology based information such as the cell 
shapes, nuclei shapes, and tissue structure is used to determine the presence of disease and 
grade (figure 3.1). Few such important morphometry based features have been summarized 
previously[130].  
Cancer is a complex and dynamic disease, and in some cases can quickly proliferate while 
evading growth suppressors, resisting cell death, developing resistance to drugs and metastasize 
to different parts of the body[131]. Due to the intricate processes taking place during cancer 
development and progression, the molecular snapshot of the disease at a specific stage could be 
descriptive of the future behavior of the tumor. With the developments in precision medicine, 
                                               




targeted therapies, imaging, computational and data visualization tools, we have a surge of data, 
which does not add to our understanding of disease when used in isolation. Therefore, it is timely 
to develop models that can integrate information obtained at various systems levels.  The idea 
that the response of cancer can be quantified in the form of mathematical or computational models 
using systems biology has been proposed before[132]. Quantitative chemical imaging (QCI) is a 
top-down approach of  systems pathology that seeks to address the current challenges in 
predicting response to therapy and outcome of the disease, as well as to develop a mechanistic 
understanding of disease development and progression, fulfilling the need to quantify tumor-tumor 
microenvironment interaction at the patient level. By providing quantitative assessment, QCI can 
play an integral part in evidence-based pathology, which seeks to aid clinical instinct by using 
evidence derived from large-scale data[133]. Using artificial intelligence models that are capable 
of combining multi-platform approaches, QCI can be used to place the information in the clinical 
and biological context, enabling patient specific interpretation.   
Biochemical characterization of tissue for developing systems pathology models is a vital 
component of any tumor prediction model. Conventionally used techniques such as genomics 
and proteomics provide a wealth of molecular information but are significantly limited in spatial 
details (figure 3.2). Many changes in tumor environment are spatially specific, for example, 
extracellular matrix remodeling [134], activation of cancer-associated fibroblasts[135] and 
angiogenesis[136].  Immunohistochemistry is useful in visualizing molecularly specific changes in 
tissue but the target needs to be known in advance and multiplexing is often not possible. The 
limitations of currently used modalities present an informational gap in current systems pathology 
models that can be filled by chemical imaging such as infrared imaging and Raman imaging 
(figure 3.2). Specifically, infrared spectroscopic imaging utilizes the interaction of light waves with 
tissue to measure the biochemical changes occurring in the tissue. Molecular bonds present in a 
material give it a characteristic chemical spectrum. This spectrum is unique for every chemical 
and therefore, can be used as a ‘fingerprint’ to identify the molecular content. When there is a 
change in the biochemistry of the tissue, the chemical constitution changes, causing changes in 
the chemical spectrum which can be measured using optical spectroscopy[137]. Optical 
spectroscopic imaging can be used ex vivo in conjugation with histology to bring together tissue 
biochemical and morphometric profiling (figure 3.3) and to enhance our prediction capabilities for 





Motivation for improving current pathology 
Inclusion of molecular information 
While morphometry works well for diagnosis, it does not have sufficient features to enable 
prognosis prediction. Developing an understanding of underlying biological mechanisms of 
disease development and progression has allowed better prediction of outcome and optimal 
therapeutic routes. For example, gene expression-based data, in conjugation with clinical data 
was shown to substantially correlate with survival in lung cancer patients[138]. The inclusion of 
molecular information has aided the clinical decision-making process[139] and has enabled 
physicians to assess risk and develop strategies for personalized care.  Few such markers are 
now extensively used in prostate cancer[140], breast cancer[7,139,141], and colon cancer[142]; 
and a comprehensive review can be found here[143].  
In addition to gene-based markers, molecular information is also available through probe-based 
techniques. Recent advances have enabled multiplexed imaging of antibodies using multiplexed 
ion beam imaging (MIBI) that utilizes antibodies tagged with isotopically pure elemental reporters, 
increasing the range of targets analyzed to up to 100[144]. In the case of small biomolecules 
where traditional antibodies can be too bulky and change functionality of the biomolecule, highly 
sensitive imaging has been achieved using stimulated Raman scattering (SRS) active vibrational 
tags[145,146], allowing for real-time imaging of live cells to study molecular dynamics.  
Determining response to therapy 
The traditional approach towards cancer therapy has been to target specific metabolic pathways 
active in proliferating cancer cells using drugs. The reductionist approach uses isolated molecules 
to target a complex disease that often does not work in treating cancer because complete 
mechanistic understanding is lacking. Many drugs developed by in vitro screening process fail at 
the clinical stage by failing to account for complex interactions in biological systems[147]. The 
animal models used as the pre-clinical testers have poor clinical significance. For example, 
angiogenesis inhibitors such as the antibodies targeting vascular endothelial growth factor failed 
in phase 3 clinical trials despite an impressive performance in animal models[148]. Anti-
angiogenesis medication such as bevacizumab was later shown to work well in a combination 
therapy regime[149,150].  This case highlights the need to develop the complete understanding 
of the mechanisms of disease and to account for patient-specific factors while designing a therapy 
regime. Because cancer can activate alternate pathways to overcome resistance, the trial and 
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error approaches of testing drug therapies have been shown to have high failure rate[151], in part 
due to inadequate knowledge of the critical interacting pathways[152]. 
The advantage of developing a systems pathology model to determine therapy response is 
twofold. First, the drug interactions can be better understood using a human disease systems 
model, which can account for biological complexity. Second, this opens up ways to tailor treatment 
to the patient, known as “personalized medicine”. This approach can enable identification of 
patients who could potentially have an adverse response to a specific therapy and outcome 
prediction while combining therapies.                                                    
Need of new ideas for prognosis  
So far, clinicians use a combination of anatomical, clinical and molecular pathology to determine 
the best course of action for a patient. Cancer outcome is typically determined by the use of stage 
and grade information. The American Joint Committee on Cancer’s (AJCC) TNM staging system, 
coding for the extent of primary tumor (T), regional lymph nodes (N) and distant metastasis (M) 
is widely used for predicting the survival in cancer.  With about 31% of all patients getting 
laboratory tests[153], an accurate interpretation of diagnostic tests is critical. Far from being 
negligible, studies have identified that clinically significant diagnostic errors occurred in about 
0.26%-1.2% cases when reviewed by a second reviewer[154,155].  In another study, about 12% 
of all examined cytologic-histologic specimen pairs were found to have errors in cancer 
diagnosis[4]. There are opportunities to improve diagnostic testing by developing tools and 
techniques to aid physicians and pathologists. The AJCC’s current edition noted the increasing 
use of nonanatomic prognostic markers and developments in personalized analytics models for 
cancer care[156], underlining the application of new concepts to address prognosis as well as 
determining the disease at an early stage. Chemical imaging-based markers are a good candidate 
for such an approach since they are independent of anatomy and enhance morphometry based 
prediction models by adding a biochemical description of the cells and tissues (figure 3.2).  
How can chemical imaging aid systems pathology? 
Chemical imaging can be used to study cancer-associated biochemical changes in the tissue 
biopsy. This approach is particularly relevant in developing systems model where both molecular 
and spatial information is necessary. There are several key pieces of information about a patient’s 
bio-physiolocial system which can be obtained with previously established methods, such as 
genomics, and proteomics. While the role of tumor microenvironment in the development and 
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progression of cancer clear, we do not yet have efficient means to profile microenvironment 
changes in the native tumor. In this section, we review the effect of tumor microenvironment in 
disease development and progression and how it has been measured using chemical imaging, 
starting with two disease-specific examples. Given the strengths and limitations of current 
technologies, optical spectroscopy proves to be a timely tool to probe the microenvironment that 
could provide high molecular and spatial detail (figure 3.2).  
Chemical imaging for biomolecular characterization at the cellular level: Breast cancer example 
Computational modeling at the cellular level is often called as systems biology. This definition 
includes the use of bioinformatics databases of gene expression, proteomics data and available 
literature related to metabolic pathways to describe cellular networks[157]. Multiple optical 
spectroscopy studies have followed this approach by studying tumor cells grown in culture and 
observing their interactions with other cell types and the extracellular matrix. For example, 
fibroblast transition when grown in a co-culture with cancerous breast epithelium cell line was 
characterized using IR spectroscopic imaging[158]. In this paper, the authors correlated α-smooth 
muscle actin expression with infrared spectra to measure fibroblast transformation in response to 
the tumor. Fibroblast transformation was induced by either treatment with transforming growth 
factor-β1 (TGF-β1) or by co-culturing them with tumor cells. The authors found spectral changes 
in the C-H stretching region (3000-2800cm-1), symmetric phosphate stretching peak (1080 cm-1) 
and asymmetric phosphate stretching peak (1224 cm-1) using which they were able to differentiate 
between normal and cancer-activated fibroblasts.  
In the follow-up study, infrared spectroscopic imaging was used to characterize the effect of 
fibroblasts in promoting cancer growth[159]. In this study, the authors developed and applied a 
3D cell co-culture system where the tumor cells interacted with fibroblasts in a controlled manner. 
Different configurations of co-cultures were studied, which altered the means of interaction 
between the tumor cells and fibroblast. The ‘mixed’ culture allowed direct cell contact between 
the fibroblasts and tumor cells, while the ‘sandwich’ co-culture allowed interaction via soluble 
factors. Using gene expression data, the authors established that the fibroblast-tumor cell co-
culture altered the estrogen receptor levels and lead to epithelial to mesenchymal transition. Post 
the molecular analysis; the authors examined the FT-IR spectra of the same 3D culture samples. 
The decrease in the C-H vibrational spectrum (3000-2800 cm-1), associated with lipids was found 
with the loss of estrogen receptor signaling. The peak associated with phosphate stretching at 
1080 cm-1 majorly contributed by nucleic acids, was found to be a marker to assess proliferation 
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in cells. This peak was shown to reduce in response to the anti-proliferative endocrine drug 
tamoxifen in hormone-responsive cells but not in hormone therapy-resistant cells. The spectral 
observations made at the cellular scale were also translatable to human breast tissue samples. 
Spectroscopic differences between patients with different estrogen receptor status could be 
observed in the epithelium specifically in the C-H region which showed similar profile to the 3D 
cultured model[159].  
In addition to observing cancer-associated changes, many other studies have sought to study the 
spectral changes in the cells as they go through various phases of the cell cycle[160–163] which 
could provide useful cell proliferation markers. These studies show that measuring the chemical 
response of cancer cells using optical spectroscopy is feasible without the loss of spatial 
information, and can be used as an in situ alternative to immunohistochemistry for tissues 
accessible with a probe such as skin, colon and the oral cavity. Using IR spectroscopy also 
automates the identification of cell types[164], thus enabling cell-type specific spectral analysis.  
Chemical imaging for tissue level characterization: Prostate cancer example 
Prostate cancer is perhaps the most frequently modeled disease using systems pathology 
approach. The currently prevalent predictive models for outcome determination in prostate cancer 
stratify risk of patients based on the biopsy Gleason score, prostate-specific antigen(PSA) levels 
and clinical stage, and have been reviewed in detail here[165]. The most critical concern while 
using approaches that heavily rely on the Gleason score is that the Gleason scoring is subjective 
since it is based on the pathologists’ interpretation[165]. In recent years, quantifying the nucleic 
localization of androgen receptor protein has improved prognosis prediction. The application of 
systems pathology in determining recurrence based risk groups has been demonstrated with the 
use of morphological, immunohistochemical and clinicopathologic data[166–168] and an 
improvement in accuracy of prediction is reported by using multimodal data. In a study to 
automate classification of cancer versus non-cancer prostate tissue samples, it was shown that 
conventional histology based diagnosis benefits from multimodal image analysis that integrates 
IR spectroscopic images with H&E images and improvement is seen in the accuracy of 
determining cancer within biopsy samples[169].  In this study, the authors first classified the IR 
spectroscopic images into epithelial, stromal and other components using supervised 
classification. Next, morphometric information from the H&E images was obtained for segmented 
epithelial cell regions by fusing classified IR image with the H&E image. Lumen and nuclei related 
features were then extracted from these images, which were useful in differentiating between 
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cancerous and non-cancerous samples, much like the procedure a trained pathologist would 
follow. This automated IR spectroscopic feature based segmentation resulted in AUC value 
greater than 0.95 on the test dataset when both IR and H&E image data was used which dropped 
to about 0.92 when only H&E data was used. 
In addition to being useful for cell-specific morphometric feature extraction, spectroscopic data 
has been demonstrated to predict the risk of prostate cancer recurrence more accurately than 
Kattan nomogram and CAPRA-S score[77]. In this study, the authors first identified a set of IR 
spectral features that had a discriminating power to differentiate between recurrent and non-
recurrent cancer cases using frequent pattern mining. By testing both epithelium IR features and 
stromal IR features, the authors found that stroma, but not epithelium had predictive capability, 
and the stromal features were spatially associated with reactive stroma. Using clinical variables 
of age at prostatectomy, Gleason sum, and pathologic stage, the authors built matched recurrent 
and non-recurrent patient pair sets. The test sample was compared with training pairs in the 
dataset to quantify whether the test sample was closer to the recurrent patient or the non-recurrent 
patient via Ranking support vector machine algorithm. Using the ranks obtained from this 
algorithm, the authors calculated the predicted probability of recurrence of the test patient, called 
the IR score. Since the IR score is an independent predictor of recurrence, it can be combined 
with other clinical variables to fit a logistic regression model given by[77] 
  (eq. 1) 
Where Y represents the binary outcome of recurrence (1) and non-recurrence (0), I represents IR 
score, A represents age at surgery, G represents Gleason grade, S represents pathologic stage 
and P represents PSA level. β1-β5 estimate conditional odds ratios for the corresponding 
variables. When used as standalone, the IR score achieved an area under the curve (AUC) of the 
receiver operating characteristic (ROC) curve of 0.73, highlighting the importance of IR spectra 
based probing of the microenvironment. This is an improvement over the previously proposed 
CAPRA-N and Kattan classifiers which performed at an AUC of 0.47 and 0.45, nearing almost 
random classification.   
Given that systems pathology models which use the currently prevalent molecular and 
morphologic markers do not perform better than postoperative biochemical disease recurrence 
nomogram and Cox regression clinical failure model[170]; these results highlight the importance 
of using optical spectroscopy based features in the systems pathology models.  
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Chemical imaging to characterize the extracellular matrix 
The extracellular matrix (ECM) is an essential component of an organ or tissue that provides it 
structure as well as chemical and mechanical signaling cues to maintain healthy structure and 
function. It has been shown that the changes in ECM are related to carcinogenesis and has been 
reviewed extensively[134,171–174]. Prolonged inflammation resulting in the activated stroma, 
changes in extracellular matrix stiffness[175,176], deregulation of specific ECM proteins[177] and 
extracellular matrix remodeling [178,179] are a few examples of changes that are associated with 
the development of cancer. Extracellular matrix close to the tumor is modified and represents a 
potential marker for risk stratification, but it is difficult to recognize changes occurring in the 
extracellular matrix using conventional histology. Remarkably, IR spectroscopy can differentiate 
between type I, III, IV, V and VI collagens, making it useful for molecular histology[180]. It has 
been shown that using infrared spectroscopy, the stromal response to developing tumor has a 
distinct spectral signature[181]. As an example, in figure 3.4, normal stroma and reactive stroma 
is identified in colorectal biopsy samples post a supervised learning step described 
previously[127,164,182]. In a malignant biopsy, the stroma neighboring the cancerous epithelium 
is identified as reactive whereas, in a normal biopsy section, the stroma neighboring the 
epithelium is morphometrically and biochemically normal. Degradation of the extracellular matrix 
via proteolysis can be localized with micrometer resolution[183]. This stromal change is significant 
in differentiating between normal, benign and malignant breast tissue[184]. Raman 
spectroscopy[185] can also be used as a tool to probe the extracellular matrix state in situ, 
achieving distinction between healthy and damaged collagen, and discrete frequency infrared 
spectroscopic imaging is emerging as a high-speed tool for rapid detection of fibrosis and tissue 
damage[186,187].  
Chemical imaging based angiogenesis identification  
Tumor angiogenesis, a hallmark of cancer[131] presents yet another avenue of information that 
can be useful in predicting the trajectory of the tumor. Tumor sustenance and growth are 
dependent on the access to blood vessels and often the tumors, and their interaction with other 
components in the tumor microenvironment create conditions that can induce angiogenic 
signaling pathway[188–192]. Imaging angiogenesis in-vivo and ex-vivo has been made possible 
by microcomputed tomography (micro CT)[193], magnetic resonance imaging (MRI), and 
optoacoustic tomographic imaging[194]. Angiogenesis can also be determined by assaying 
angiogenic growth factors such as VEGF which is amenable to multiplex molecular profiling 
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systems, while hypoxia-specific conditions, which are the key regulators of angiogenesis[195–
197] can be measured in vivo using near-infrared optical imaging probes[198]. Variations in tissue 
biochemistry due to hypoxia and low pH conditions can be measured by assaying glucose and 
lactic acid levels in FT-IR spectroscopy. Glucose content is found to decrease linearly with 
distance while lactic acid content increases as we move away from the blood vessel[199], making 
FT-IR a candidate to perform microscale molecular imaging to visualize angiogenesis. In addition 
to imaging metabolites for assessing angiogenesis, triple helix and β-turn content of the 
secondary structure of blood vessel proteins has been shown to be a potential FT-IR based 
marker for imaging angiogenic tumors[200].  
New and emerging concepts  
In addition to the currently available literature on the mechanism of cancer initiation, growth and 
spread, new and emerging concepts provide an opportunity to enhance diagnosis and prognosis 
prediction. With research still underway on the clinical impact of these factors, this section outlines 
potential areas where developing optical spectroscopy based analysis methods can be useful.   
Self-seeding 
Metastasis to distant sites requires colonization of circulating tumor cells in unfavorable 
conditions. In contrast, the primary site of the tumor has more welcoming conditions[201]. Re-
infiltration of circulating tumor cells(CTC) to the primary site, known as self-seeding, is facilitated 
by tumor-derived cytokines that act as CTC attractants[202]. Because self-seeding enriches the 
tumor with aggressive cells, it is likely that self-seeding can worsen prognosis. A large-scale 
study[203] published recently reported that the overall survival of patients with metastatic cancer 
who underwent local therapy was improved as compared to patients that did not receive local 
therapy. This distinction could be due to reducing tumor burden and interrupting self-seeding 
when local treatment is given[203]. There is limited clinical evidence with regards to the effects of 
tumor self-seeding, and it is not possible to directly evaluate self-seeding extent in patients. CTCs, 
which are vital in the self-seeding process can be monitored with microfluidic devices[204] using 
blood[205–207] and through other technologies outlined in these reviews[208–210]. With the 
recent advancements in the CTC capture technologies, it is likely that these devices would soon 
have clinical applications using patient’s blood or biopsy[211] and potentially impact clinical 




Alterations in metabolism can facilitate uncontrolled tumor growth[131]. Otto Warburg first showed 
that glucose consumption is heightened in tumors when compared to normal tissues[213]. Much 
research has been done in this field since the first observation, and is reviewed in these 
articles[214–217]. The altered metabolism in the tumor has been of interest in developing 
diagnostic techniques as well as in identifying therapeutic targets[218,219]. Positron emission 
tomography (PET) is a routinely used clinical technique that uses 18F-fluorodeoxyglucose (FDG) 
to measure glucose metabolism.  FDG-PET can, therefore, identify biochemical changes at the 
molecular level in vivo. Due to low sensitivity and modest specificity, FDG-PET is not a viable 
diagnosis tool. However, it can be useful in characterizing the disease once a diagnosis has been 
made[220]. FT-IR spectrometry can assist in studying metabolic changes in tissue, associated 
with quantification of metabolic molecules such as glucose and lactic acid. In a study to test this 
approach, the researchers found that FT-IR spectrometry was able to detect nanomolar 
concentrations of metabolites within biological samples[199]. Interestingly, premalignant spectral 
changes in cells are detectable much earlier than morphologic changes in the cells[221,222] 
constituting of significant variations in lipids and proteins and further research in this area could 
shed light on the changes undergone by the tissue temporally as it changes from normal to a 
malignant state. A broad spectrum of small biomolecules such as glucose, choline, fatty acids 
and amino acids can be visualized by using Raman-active probes with high specificity and 
sensitivity, further enhancing our insights to metabolism in the tumor environment[145,146].  
Use of mathematical methods 
The current medical diagnosis has been enhanced by the introduction of ‘-omics’ data. The 
clinicians now consider histopathology based morphometric information in conjugation with 
molecular information and apply their own experience and knowledge to reach a 
diagnosis[223,224]. This behavior of pathologist can be replicated using machine learning 
approaches to develop probabilistic models to determine diagnosis and predict prognosis. One 
way to do this is to use Bayesian parameter estimation to calculate the weight of various response 
variables available through experimental data[225]. This approach produces posterior probability 
distribution that can predict system behavior.  A computational approach to translate metabolic 
networks into mathematical models has also been explored[132]. Briefly, two mathematical 
models can be used to predict the response of a biochemical system. The first is the Systems 
Theory (S-system) approach where differential equations are used to model a non-linear system. 
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The second approach, based on fuzzy logic is based on probabilistic models that output results 
between 0 and 1, accommodating for imprecision in biological systems. When modeling cancer 
through systems pathology approach, we need spatial as well as temporal factors[226]. Beginning 
with the development of the disease due to perturbations in the system: often due to the loss of 
tumor suppressor gene functions, to the growth and progress of cancer to invasive and metastatic 
stages; each stage of cancer presents an altered system. In response to therapy, a system can 
change over time as the disease develops drug resistance. Dynamic modeling or mechanistic 
modeling used in systems pathology employs previously established mathematical models such 
as the law of mass action and equations describing enzyme kinetics[227]. These models can be 
used to predict temporal response[227] albeit at molecular scales. Given the complexity of the 
system and evolving nature of cancer in response to microenvironmental changes, stochastic 
modeling of the systems have gained popularity[228–230].   
In either of these systems, the input should be quantitative, multiscale and multidimensional, 
encompassing several levels of the system, and the prognostic model should include the ability 
to identify and explain factors that were predictive. This requirement makes the development of 
such models tricky, needing a highly complex and interconnected model. One way to handle the 
issue of complexity is by assembling small quantifiable pieces to come up with a single predictive 
model. Imaging provides opportunities to obtain quantifiable chunks of information. One way of 
integrating imaging data to mathematical models was proposed by Atuegwu et al (2010) and Gore 
et al (2010) where imaging data from multiple modalities was integrated as initial conditions to 




where Ni(t) represents the number of tumor cells in the ith voxel as a function of time, kim term 
represents the net ‘transfer constant’ of cells from the ith voxel to the mth voxel obtained using 18F-
fluoromisonidazole PET, μd,i represents the death rates of tumor cells obtained via 99mTc annexin 
V imaging, and μp,I represents the proliferation rate obtained via fluorodeoxythymidine PET (FLT-
PET)[231]. This model could simulate the tumor characteristics in a rat brain as a function of 
space and time, where the initial parameters were set by imaging data specific to the subject, 
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potentially leading to patient-specific predictions. This example shows the remarkable prediction 
capability that can be achieved by integrating imaging data. The prognosis determination example 
discussed in equation (1) shows that incorporating biomolecular data with clinicopathological data 
and other predictors renders an informed, quantifiable and accurate prediction. Together, models 
that can predict tumor growth, drug response, account for temporally and spatially specific 
microenvironmental changes and patient-specific factors can lead us to precise disease 
management.  
Conclusions 
There has been a rapid development of analytical instruments to detect, diagnose and study 
cancers. CT and MRI can be used to perform anatomic imaging, PET and single photon emission 
tomography (SPECT) are useful in determining biochemical characteristics, and these techniques 
are often used in a combination called as multi-modality imaging to collect a broad spectra of 
information[233,234]. Complementing the conventional tools of biopsies and histopathology, 
clinicians can now utilize several of these tools to reach a decision. In addition to the macro-level 
data provided by these imaging modalities that help in determining the existence of tumor and 
basic biochemistry, a systems pathology approach requires information at the molecular level, 
such as that provided by proteomics and genomics data. In addition to the ability to probe the 
tumor microenvironment by delivering spatially specific biochemical data, chemical imaging can 
provide information independent of histopathology and clinicopathological data which has been 
shown to improve recurrence prediction[77].        
Perhaps the most challenging step in systems pathology approach for disease analysis is the 
modeling of the system. Many mathematical methods have been developed to explain specific 
components of the cancer development process such as self-seeding[235], angiogenesis[236–
238] and cancer metabolism[239–241]. At the systems pathology level, the model needs to 
encompass multiscale, multimodality quantitative data (figure 3.5). The availability of data is no 
more a challenge, rather, identifying useful data and eliminating redundant information is 
necessary before model implementation. Mathematical models are useful at unimodal stages, 
where we have an understanding of the process. When many modalities are combined, the effect 
of such combinations become hard to interpret manually and would require machine learning. 
Deep learning techniques can be used to consolidate the data and form meaningful conclusions 
in instances where the bottom up equation driven models fail; through the combination of 
modalities on space, time and molecular axis in a top-down approach. The next driving 
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developments in this field should be focused on the precise quantification of the microenvironment 
using patient biopsies, and a large-scale collaborative effort to realize focused data collection and 
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Figure 3.2: Imaging and molecular analysis methods compared against the molecular and spatial 
details offered by them. Spatial detail is associated with the spatial resolution offered by the 




Figure 3.3: IR spectroscopy brings together morphometry and biochemical profiling of the 
tissue. Each pixel of the image has a spectrum. Different cell types such as myofibroblasts 
and epithelium have different IR spectra, which are useful in assessing chemical 
differences and changes undergone by them. 
 
Figure 3.4: Morphometric and biochemical differences exist between normal and cancer-
activated (reactive) stroma. These differences can be used to identify normal stroma and reactive 
stroma in infrared spectroscopic images. In figure, normal stroma is identified in a normal biopsy 
core (left) and reactive stroma is mapped on a malignant biopsy core (right). Note the 











Figure 3.5: Several anatomic and non-anatomic assessment techniques provide useful 
pieces of response information. When used in isolation, these techniques cannot predict 
the complete systemic response. Therefore, there is a need to integrate data obtained 
through various measurement methods into a unified systems pathology model. 
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CHAPTER 4: MICROENVIRONMENT AND TUMOR SPATIAL INTERACTION MODEL USING 
QUANTITATIVE CHEMICAL IMAGING PREDICTS COLORECTAL CANCER PATIENT 
OUTCOME7 
Abstract 
The tumor microenvironment and its interaction with the tumor is indicative of disease progression 
but has not been clinically applied due to lack of objective assessment criteria. The proximity 
associated effects of the tumor to its microenvironment which can explain the long-term behavior 
of tumor remain to be developed. In this work, we utilized the biochemical sensitivity of infrared 
spectroscopic imaging to segment colon tumor biopsies into major tumor microenvironment 
components in a 320 patient cohort. A risk score defined by the extent of stromal reaction and its 
interaction with the tumor stratified overall survival in patients (p-value 0.0003), and disease free 
survival (p-value 0.0274). The risk score performed independent of stage and grade information 
of the patient with the hazard ratio of 1.88 at p-value of 0.011, almost doubling the risk of death if 
the patient had risk score higher than 3.53. Our results objectively quantify and model the spatial 
interaction of tumor with its microenvironment, which is predictive of the patient outcome.  
Introduction 
With the developments in precision medicine, targeted therapies, imaging, computational and 
data visualization tools, we have a surge of clinical data, which is often under-utilized when treated 
in isolation. Due to the intricate processes taking place during the development and progression 
of cancer, the tumor microenvironment is continuously interacting with the tumor and changing 
dynamically[242–244]. Several key changes in the tumor microenvironment, such as cancer-
associated fibroblasts, stromal remodeling as well as immune cell infiltration play a role in 
promoting or resisting tumor growth[131]. Specifically in colon cancer, the fibrotic stromal 
response known as the desmoplastic reaction  has been linked to survival, cancer aggressiveness 
and degree of invasion [12,245–247]. Although such survival stratification is of high utility in 
determining the outcome, it is clear that the stromal remodeling in the tumor microenvironment 
does not act alone in promoting aggressive tumor behavior. The biomolecular snapshot of the 
tumor in its native microenvironment captured in conjugation with the spatial distribution could be 
descriptive of the patient outcome but has not been explored to date. 
                                               
7 In preparation for publication as Tiwari, Saumya et al. “Microenvironment and Tumor Spatial Interaction Model Using Quantitative 
Chemical Imaging Predicts Colorectal Cancer Patient Outcome.” 
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Traditionally, after surgical resection/biopsy and molecular staining, pathological interpretation is 
used to determine patient outcome in terms of grade and stage (figure 4.1a,b). In contrast, 
quantitative image analysis seeks to evaluate the tissue biopsy images in the form of quantifiable 
variables. Such investigations can help us develop an understanding of tumor-microenvironment 
interaction[248] and give us insights into the spatio-specific tumor progression mechanisms. 
Previous quantitative image analyses predicted patient survival by merging information from 
biopsy images with molecular data[249] and demonstrated capturing heterogeneity in cell 
populations[250]. Despite recent advances, the rich biochemical details present in the tumor 
cannot be utilized to predict patient outcome without a priori knowledge of molecular targets. 
Other studies have also identified the link between desmoplastic response in biopsy specimens 
and the depth of invasion in early colon cancers[12,247]. Although such stratification is of high 
utility in determining the outcome, the intra- and inter-observer agreement in deciding the 
desmoplastic reaction is low[251]; varying between 0.30 to 0.71. This lack of concordance found 
in colon cancer underlines the need to develop objective methods to evaluate the stromal 
reaction. In addition, current models of quantitative image analysis techniques rely on tissue 
staining, and suffer from roadblocks such as low contrast, need for annotations by pathologists, 
as well as multiplexing limitations.  
Quantitative chemical imaging (QCI) seeks to address the current challenges in predicting patient 
outcomes without a priori information about the molecular targets, and fulfill the need to quantify 
tumor-tumor microenvironment interactions. In particular, chemical imaging using Fourier 
transform infrared (FT-IR) spectroscopic imaging allows spatially specific multiplexed chemical 
profiling of samples  without the need for stains (figure 4.1c). Cell populations and micro-
environmental features show differences in their infrared absorbance spectra[44,74,75,127] 
owing to the inherent biochemical differences between them. Spectral profiles collected from IR 
imaging enable sensitive and specific identification of tumor and tumor microenvironment 
components[164], which can be mapped onto the tissue using artificial intelligence(AI) for robust 
image quantification (figure 4.1d).   
In this work, we hypothesized that by utilizing both molecular as well as morphometric features in 
patient tumor sections, we will capture the state of the tumor-microenvironment interaction, thus 
predicting patient outcome. Our work on quantitative chemical imaging provides a robust 
approach to capture and model the biochemically specific spatial interactions to predict long-term 




Infrared spectroscopic signatures identify tumor stromal components 
In this work, we aimed to develop a Fourier transform infrared spectroscopic imaging based 
machine learning model which allowed for the mapping of several biochemical transformations in 
the tumor stroma onto the tissue biopsy image. High definition Fourier transform infrared imaging 
was used to image eight tissue microarrays, collecting the infrared spectrum of every 1µm2 pixel. 
The spectral signatures associated with desmoplastic reaction, normal stroma and lymphocytes 
and seven other tissue components were obtained by matching regions annotated by a 
pathologist on H&E image to the infrared spectroscopic images (Supplementary figure 4.1a). 
Figure 4.2a shows the average absorbance spectra of the ten classes that we identified in colon 
tissue. The most substantial differences between classes were observed in the fingerprint region 
between 982-1480 cm-1. The most prominent differences were seen in mucin and mature 
epithelium vs. all other classes in 980-1182 cm-1. This distinction is arising from mucin, which is 
a glycosylated protein showing strong absorbance at 1038cm-1[252]. Mature epithelium (goblet 
cells) containing cytoplasmic mucin also registered glycoprotein associated absorbance. As seen 
from the spectra, and the images of colon adenocarcinomas in subsequent sections, this 
functional property of mature epithelium was lost in the malignant or proliferative epithelium. 
Another major region of difference was found in the CH,CH2 and CH3 stretching motion peaks 
around 2800-3000 cm-1 which has been previously noted as well.  
While some of the differences shown in figure 4.2a arise due to biochemical differences between 
histologic classes, we also accounted for other sources of variations in the samples. In our study, 
we considered patient, array and histological class labels as factors affecting the infrared 
spectrum and performed ANOVA using the framework described previously[253]. Spectroscopic 
data collected from three training arrays were utilized for this approach (Supplementary figure 
4.1b). From this analysis, using 0.05 as significance level, we removed all spectral metrics where 
array and patient associated variances were statistically significant. Two hundred and fifty-six 
spectral metrics were excluded from the ANOVA analysis. Following analysis of variance, we 
performed an additional step of feature reduction using minimum redundancy maximum relevance 
(mRMR). Feature reduction was required to (a) Reduce computation time (b) Remove redundant 
features (c) Prevent overfitting.   Briefly, this model used the correlation between variables and 
outcomes as a means to identify variables that were the most predictive of the class label, and 
the correlation between variables to identify variables that will cause the least redundancy in the 
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system[254]. Using mRMR, we were able to reduce the number of variables that ensured better 
model fit and mitigated overfitting. Post ANOVA and mRMR, we retained 50 spectral metrics that 
were used for developing histology classifier model. These spectral metrics have been listed in 
Supplementary table 4.1 with accompanying definitions. From this table, we observed that the 
retained spectral metrics were most frequently defined from the fingerprint region between 1053 
-1593 cm-1 and 2939-2987 cm-1; consistent with our observations from fig 4.2a.  
Finally, we looked at the differences between the classes in the 50 spectral metrics that were 
chosen following ANOVA and mRMR (Fig 4.2b). We calculated average spectral metric values 
across each class in the training set, discretized the values in each of the spectral metrics by 
equal depth binning and performed hierarchical clustering. Data were first clustered along the 
classes and then along the metrics using Euclidean distance metric and farthest neighbor 
distance linkage between the clusters. The heat map in figure 4.2b shows the observed clustering 
patterns, where each row corresponds to a spectral metric, each column corresponds to the 
histologic classes, and the intersection indicates the metric discrete value level for the specific 
metric in that class. As expected, mucin and mature epithelium clustered close together, while 
blood had the most distinctive features, owing to the absence of nucleic acids. The two most 
distinct spectral clusters from the hierarchical clustering are labeled C1 and C2 in figure 4.2b. The 
difference between these clusters can be understood in terms of the spectral regions that were 
most frequently involved in defining the metrics for these clusters (Supplementary Table 4.1). A 
similar idea has previously been described as spectral barcoding, where IR spectra are used 
directly to identify discriminative frequencies by unsupervised analysis[255]. From this analysis, 
the majority of fingerprint region between ~982-1580 cm-1 and CH stretching region between 
2800-3000 cm-1 clustered together as C1 while OH-NH region between ~3000-3700 cm-1 and 
amide I region clustered together as C2. From the metric expression patterns of the classes in C1 
and C2, it is clear that further association of spectral metrics exist. While 50 metrics are used to 
develop this classifier, it indicates that there is a possibility of trimming down the dataset further 
to improve the speed of imaging by utilizing discrete frequencies[256].  
Biochemically specific spectral machine learning classifier retains high specificity and sensitivity 
when tested on independent TMAs 
We used Random Forest supervised learning algorithm to develop the histology classifier with 
ten classes, labeled as epithelium (mature), mucin, epithelium (proliferative), necrosis, reactive 
stroma, blood, inflammatory cells, non-reactive stroma, muscle and loose stroma. The leaf size 
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and feature size determined for optimal fit were 500 and seven respectively, with 50 total features 
and an ensemble of 50 decision trees (Supplementary figure 4.1c). We have observed that 
increasing the number of trees beyond this did not give a proportional increase in accuracy and 
followed the law of diminishing returns described before[257,258]. This classifier was trained on 
four arrays (a1,a2,a3,a4) and 126,946 pixels per class, calibrated on two additional arrays (a5,a6) 
and tested on two independent arrays (a7,a8). For both training and testing area under the curve 
(AUC) of the receiver operating characteristic (ROC) curve was evaluated. The results from this 
classifier are shown in figure 4.2c. The performance of the histology classifier was evaluated at 
pixel level using receiver operating characteristic curves, using pathologist annotated regions as 
the ground truth. High specificity and sensitivity were obtained, with the training data classified 
with an average AUC of 0.94, and the validation data classified with an average AUC of 0.93 
(figure 4.2c). We also evaluated the importance of metrics in classification by measuring the 
increase in prediction error in calibration data (a5, a6) when the values of the metric were 
permuted across all data. Interestingly the most important features identified in this manner (figure 
4.2d) were associated with amide I and amide II regions, such as normalized amide II peak height 
at 1545 cm-1, area to height ratio of amide II peak region between 1591-1757 cm-1 and 1645 cm-
1, peak centroid position of amide II peak and the normalized intensity of 1645 cm-1 band. The 
cohort used in this study comprised of paraffin-embedded tumor tissue of the surgical specimens, 
where normal-appearing colorectal mucosa and lymph node metastases were also sampled for 
some patients. Figure 4.2e shows the comparison of H&E images with corresponding IR histology 
classified images for normal colorectal mucosa, invasive tumors, and lymph node metastases.  
The classified images show good correspondence with the H&E images for the three types of 
tissues. Benign colorectal mucosa is a good example of the diverse tissue components present 
in the colon, with well-formed mature epithelium glands and normal appearance of (non-reactive) 
stroma. Mucin can be seen within the glands. In invasive tumors, the glandular structure formed 
by malignant epithelium is distorted or lost, and the stroma around the tumor is modified due to 
desmoplastic reaction (reactive stroma)[12]. All of these histologically important features were 
classified correctly. We were also able to identify the presence of malignant cells in samples from 
lymph node metastases, indicating superior performance compared to H&E based 
benchmarks[259]. 
The extent of desmoplastic reaction, as well as its proximity to tumor cells, is associated with 
survival 
To understand the scope of microenvironment effects on patient survival, we developed the 
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supervised classification models that performed with high specificity and sensitivity to map stromal 
changes onto the tissue biopsy images. We classified stroma as reactive, where the desmoplastic 
reaction was present, non-reactive, where the desmoplastic response was absent and as 
lymphocytes where lymphocyte specific spectral signatures were observed. The desmoplastic 
reaction was identified using previously established criteria, namely enrichment of “plump” 
fibroblast, the organization of stroma and presence of other cell types[260,261]. The pathologist 
making the ground truth categorization was blind to all accompanying clinicopathological data 
including the stage. Next, we used the classified images obtained from the supervised classifier 
to measure quantitative spatial features (Fig 4.3a). Distance feature (d) was defined as the 
distance to the closest microenvironment component from the tumor pixel, averaged over 500 
random tumor pixels in 30% downsampled image. The area feature (N) was defined as the total 
number of pixels classified as a specific microenvironment component in a radius R from 500 
randomly selected tumor pixels as the center. The area was normalized to πR2 to accommodate 
for centers close to the biopsy edge. We set the R for our analysis to be 600µm, based on our 
empirical observation that in comparing invasive and normal cores, any radius above 439µm 
captured the spatial characteristics between the biopsies. Finally, the interaction feature (M) was 
defined as the product of d and N averaged over 500 randomly selected tumor pixels as the 
center. For these tests, we only selected cores with at least 5% malignant epithelium by area. 
Each of these features was dichotomized by splitting at the median value of 3.53; giving us two 
patient groups per variable per microenvironment component tested. Next, we performed the 
univariate log-rank test and multivariate Cox regression analysis to determine if there was a 
significant difference in the survival of the two groups (Table 4.1). From the two tests, only features 
measured with reactive stroma as the microenvironment component showed a significant 
difference in survival. The two features that showed significant differences in the survival were 
NRS and MRS, with p values of 0.006 and <0.0005. From multivariate Cox regression model of time 
to death (Table 4.2), the interaction metric variable MRS showed an independent effect on 
increasing hazard for the patient when modeled with other known covariates such as the stage, 
grade, age, sex, and source, with a p-value of 0.011. The p-values for three overall tests, the 
likelihood ratio test, Wald test, and log-rank test were all less than 4e-11, indicating that the model 
was significant, rejecting the null hypothesis that all of the coefficients() are 0. In the multivariate 
Cox regression analysis, the hazard ratio, evaluated as exp() was in the range 1.15-3.07, 
indicating a strong relationship between the high values of interaction feature MRS and increased 
risk of death. Thus, higher values of interaction feature MRS, calculated from the patient biopsy 
images are associated with adverse prognosis. Other features that showed significant association 
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with risk of death were stage and age, as expected. By contrast, the tumor grade evaluated on 
whole surgical biopsy images by pathologists did not show significant association with increased 
risk when modeled with other covariates.  
Fig 4.3c shows Kaplan-Meier survival curves for overall survival and disease-free survival for all 
three features calculated for tumor’s interaction with reactive stroma. From univariate log-rank 
test, both NRS and MRS showed a statistically significant difference in overall survival, while only 
MRS showed a statistically significant difference in disease-free survival. The role of stromal 
reaction and its interaction with the tumor in predicting disease-free survival indicates an 
association with aggressive tumor behavior. By performing two-sample t-test (Table 4.3) on 
continuous variable MRS grouped by stage, we discovered that the mean value of MRS for reactive 
stroma was significantly different between Stage 2 and Stage 3 at 0.05 significance level (p-
value=0.00142 and power= 0.9) and between Stage 2 and Stage 4 (p-value= 0.00243 and power 
=0.87). Thus, we can reject the null hypothesis that there is no difference between the means of 
the above groups. Several other stage grouped combinations were tested, but statistical 
conclusions could not be drawn due to low power. When stage 1 and stage 2 patients were 
combined (low stage) and tested against stage 3 and stage 4 patients combined (high stage), we 
observed a significant difference in the means. Two sample t-test on combining these groups had 
a p-value of 0.0012 at 0.90 power, confirming the observation. We also tested other histological 
classes following the same procedure and found that there was no difference between the means 
of spatial features with respect to the stage.  In addition to the two-sample t-test, we performed 
Mann-Whitney test, which does not assume normal distributions and tests whether the patients 
are sampled from populations with identical distributions. From this test, we confirmed that the 
distributions of stage 2 and 3, stage 2 and 4, and low stage vs. high stage were significantly 
different.  
Discussion  
The mechanism governing tumor invasion and its interaction with the surrounding stroma and 
stromal cells is complex and not clearly understood. Dedifferentiation at the invasive front of the 
tumor is often the beginning of metastasis[262]. Several spatially specific features of solid tumors, 
such as tumor structure, and proximity related effects cannot be accounted for in traditional 
molecular assays. Quantitative image analysis using histological stains has previously been 
proposed for breast cancer but is limited by the molecular information content of the H&E stain, 
and artifacts introduced at sample preparation, staining and imaging steps[249]. In contrast, 
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infrared spectroscopic imaging provides molecular information in a spatially specific context[263], 
without extensive sample processing or staining, enabling us to identify critical biochemical 
changes in the tissue image. To utilize such a technique for quantitative image analysis, it is 
crucial to ensure that the biochemical changes associated with activation of stroma are accurate 
and reproducible. The purpose of our supervised machine learning approach was to ensure that 
regions of interest in patient biopsy images were identified with high accuracy. Human patient 
samples are heterogeneous and biochemically complex, with diversity arising due to the inter-
patient variations, biological heterogeneity and patient-specific disease development and 
response[35]. There are also effects introduced by the systems used to probe the samples, such 
as noise in signal measurement, differences in sample preparation, and several other factors not 
documented so far[94,264]. When developing a supervised classification model to identify 
histological classes, it becomes especially imperative to analyze sources of variance to identify 
spectral regions where histologically irrelevant variations are present and significant. Following 
ANOVA and mRMR to perform feature reduction, we developed a random forest-based 
supervised classification model, where we achieved high specificity and sensitivity in classifying 
ten histological segments in colon biopsy images. At pixel level, this classifier performed at an 
average AUC of 0.93 when tested on an independent sample set. This is higher and significantly 
more multiplexed than other proposed digital pathology approaches using H&E images where the 
benchmark performance is noted for deep learning classifiers at an AUC of 0.93 in identifying 
metastatic tumor in lymph nodes as the two components[259]. 
While general tissue organization and structure is typically assessed by the pathologist at the time 
of examination, this is largely subjective[251,265,266]. Several outcome associated image 
assessment criteria, such as nuclear to cytoplasmic ratio of molecular markers[267], cellular 
proportions[268], and measuring immune infiltration[269,270] have been proposed. These 
procedures often require additional pathologist and laboratory work and do not provide 
consideration for tumor-stroma interaction. Even established prognostic associated features have 
not found footing in clinics due to lack of objective assessment criteria. For example, previously, 
Ueno et al. [260] categorized stroma in colon biopsies into mature, intermediate and immature 
based on the fibrotic stromal response. Using this stratification, they showed that five-year survival 
rates were significantly lower for patients with high desmoplastic reaction. Despite the 
identification of the link between desmoplastic reaction and the depth of invasion in colon 
cancers[12,247], an objective and reproducible scoring system is undeveloped, largely due to the 
concerns arising from lack of concordance[251].  
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Unlike other predominant cancers where molecular markers have established a role in 
determining the outcome and therapy options[7,271], the criteria to determine the patient 
outcomes in colon cancers is less direct. The goal of this work was to understand how the changes 
in the tumor microenvironment and their interaction with the tumor are linked to the patient 
outcomes by studying the tissue biopsy image. This work draws on the spatially specific molecular 
assessment provided by infrared spectroscopic imaging combined with machine learning 
approaches for robust identification of tissue areas as well as statistical methods to determine the 
underlying mechanisms. We studied multiple tissue-microenvironment components and found a 
significant association between the extent of stromal reaction and patient outcome. The links were 
much more pronounced in our interaction model, which intuitively models tumor structure 
concerning outcome associated microenvironment component. Multivariate Cox regression 
model showed that the risk of a patient presenting with high MRS biopsy images increased 
independent of stage. Univariate log-rank test showed a significant difference in overall as well 
as disease-free survival of patient groups stratified on the basis of the MRS score. From t-test and 
Wald test, we see an association between the patient’s stage and the MRS score, confirming our 
hypothesis that our model is capturing the switch of tumors to a more aggressive behavior by 
monitoring its interaction with its microenvironment. Thus, our work provides an objective and fully 
automated image assessment criteria to assess microenvironment-tumor interaction. We show 
from our work that there is abundant prognostic information available in a single tumor biopsy 
snapshot, which currently remains clinically underutilized. Although our spatial interaction model 
performs very well in stratifying patients, there are many unexplored factors that could potentially 
stratify patients further. For example, IR spectroscopic imaging is limited by spatial resolution that 
can be achieved, as well as the level of molecular detail that can be recorded. Finer molecular 
differences within the reactive stroma as well as cellular heterogeneity in the tumor itself  should 
be probed by combining imaging and molecular assessment modalities. We also anticipate that 
IR imaging-based quantitative image analysis can also provide key insights into several other 
cancer types, especially in cases where outcome associated molecular markers are lacking.  
Conclusions 
The tissue biopsy is a snapshot of the tumor in its native habitat. The complex biochemically 
specific interaction between tumor and tumor-microenvironment is a key determinant of tumor 
aggression. In this study, we identified the infrared spectroscopic signatures of ten unique 
histological segments present in colon biopsies and mapped them onto the tissue image. We 
stratified the overall patient survival independent of stage, grade and age by modeling the extent 
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of desmoplastic reaction and its interaction with the tumor cells. This study demonstrates 
reproducible and objective evaluation of risk-associated features using QCI. This work is 
especially critical for clinical evaluation of tumors that do not have defined patient outcomes 
associated with molecular features. By providing quantitative assessment, QCI can play an 
integral part in evidence-based pathology, which seeks to aid clinical instinct by using evidence 
derived from large-scale data[133]. Using artificial intelligence models that are capable of 
combining multi-platform approaches, QCI makes it possible to place the information in the clinical 
and biological context, which augments the current clinical analysis by harvesting the full potential 
of big data. With recent developments in the field of chemical imaging that enable stainless tissue 
characterization at clinically desirable speeds[43,45,187], we anticipate applying quantitative 
chemical imaging approaches in clinics, allowing automated diagnosis and outcome predictions.  
Methods 
Sample preparation 
The patient cohort used in this study comprised of 320 anonymized patients undergoing elective 
surgery for colorectal carcinoma. Of these, 158 patients were females, and 162 patients were 
males. Cores of 1 mm diameter were sampled for each patient from representative invasive areas 
of paraffin-embedded blocks and were used to construct eight tissue microarrays(TMA). For some 
patients, normal colon mucosa samples were also included. This cohort has been used 
previously[272] and described in detail in the cited reference as Cohort II. For IR spectroscopic 
imaging, a 10 µm thin section of each of the TMAs was obtained on barium fluoride substrate. A 
consecutive section was collected on a glass slide for hematoxylin and eosin (H&E) staining. Due 
to the IR absorbance of paraffin at the 1462 cm-1[44], before scanning, paraffin was removed by 
initially dripping the slide with cold hexane followed by complete submersion in continually stirring 
hexane for 48 hours at 40ºC where the solvent was renewed every 3 hours. The disappearance 
of the representative peak over several locations on the slide confirmed the dissolution of the 
embedding medium. For supervised classification, data was annotated by labeling histologic 
classes on H&E images by collaborating pathologist. These annotations were manually copied 
on the infrared spectroscopic images and served as ground truth.  
Imaging 
High magnification images were taken on Agilent Stingray imaging system in high magnification 
mode. This microscope was equipped with 128x128 focal plane array MCT detector. Each pixel 
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of size 1.1 µm was averaged over four scans, and the background spectrum was acquired at 120 
scans per pixel on a clean area of the slide. IR spectroscopic images were collected at a spectral 
resolution of 4 cm-1 and step size of 2 cm-1 in the spectral range 900-3800 cm-1, providing 1506 
bands in the absorbance spectrum.  
Preprocessing 
After stitching the image tiles, noise reduction was performed using minimum noise fraction (MNF) 
transform[94]. Savitzky Golay 9 point smoothening, baseline correction, and normalization to 
amide I peak at 1650 cm-1 was done for each core in the TMA.  The spectral data were converted 
to spectral metrics using methods described previously[44,75]. Briefly, we calculated spectral 
metrics as ratios of peak heights, peak area and heights, peak areas, and centroid wavenumber 
locations of the peaks. In total, we defined 418 spectral metrics.   
Feature reduction 
In the first stage of feature reduction, we performed analysis of variance(ANOVA) using a nested, 
random effect interaction model on three arrays (a1,a3,a4) using ground truth to label classes, 
patient, TMA and patient core numbers. Since specific patients were only found in particular 
arrays and each patient had multiple cores, the nesting order was Array, Patient, and Patient-
specific core. For this analysis, the classes used were malignant epithelium, necrosis, and 
reactive stroma since these classes were most commonly observed in cores. From ANOVA, we 
determined spectral metrics where inter-array, inter-patient and inter-core variations were 
significant at 0.05 significance level and removed these from the analysis. One hundred and sixty-
two metrics were retained after this stage. In the second stage, we used minimum redundancy 
maximum relevance algorithm (mRMR) in R to further remove redundant and irrelevant features. 





where xi represents ith feature in full dataset X, y represents the output variable (class label), 
and I represents mutual information given by: 
𝐼(𝑥, 𝑦) = −
1
2
ln⁡(1 − 𝜌(𝑥, 𝑦)2) 
The next feature is added to feature vector S by finding the feature with minimum mutual 
information with respect to all the prior features in S and maximum mutual information with respect 
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to the class label. This is represented as: 






Applying this using the mRMRe package[273,274] in R, we found a set of 50 features that were 
relevant to the classification problem while minimizing the redundancy in the data. 
Supervised classification: In the model learning step, we defined pixel labels for each cell type by 
duplicating annotations from H&E stained sections as marked by an expert pathologist onto IR 
spectroscopic images. Four arrays were used for training (a1, a2, a3, a4). We used a random 
forest algorithm for supervised classification in Matlab 2016a. To address fitting issues in the 
classifier such as high bias or high variance, we used two additional arrays (a5, a6) to perform 
optimization of parameters. The parameters that we optimized in the random forest were (a) Leaf 
size: size of the group at which decision tree stops splitting further, and (b) Feature size: number 
of features sampled by the tree randomly for performing the split. The parameters were optimized 
by calculating the error in classification for both training and calibration sets for multiple leaf sizes 






∑ 𝑤𝑗𝐼(𝑦𝑗 ≠ ?̂?𝑗)
𝑛
𝑗=1  
Where e represents error, w represents the weight of the class, n is the number of classes, y is 
the true class label, ŷ is predicted label, and I is indicator function. Parameters that minimized 
calibration error and maintained low training error was chosen as optimal. The fully developed 
supervised model with optimal parameters was validated by two independent arrays (a7, a8). 
Progression analysis 
Classified images of invasive carcinoma cores from all eight TMAs were used for studying tumor-
stroma interaction. A total of 220 patients were analyzed using biopsies containing reactive or 
nonreactive stroma and at least 5% proliferative epithelium by area. If multiple cores from the 
same patient were present, means over all available cores were calculated. Three risk-associated 
features were defined to assess the tumor-stroma interaction. The first risk variable was distance 
metric (d) and measured as the closest encounter distance of the malignant epithelium pixel to 
the stromal element being probed. Risk variable area metric (N) was measured as the normalized 
pixel count of the stromal component being probed in a circle of radius R determined 
experimentally. Risk variable interaction metric (M) was measured as the interaction of the two 
features d and N for each pixel. Five hundred random pixels of malignant epithelium were chosen 
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from each of the 30% downsampled classified IR image to calculate the features. Three stromal 
elements, the reactive stroma, lymphocytes and normal stroma were evaluated separately for 
their role in determining outcome. Each risk associated variable was converted to a dichotomous 
categorical variable by splitting at the median and evaluated for significance by univariate log-
rank test and multivariate Cox-regression analysis in R using package ‘survival’[275]. Power 
analysis was performed in R using the package ‘powerSurvEpi’[276]. Two sample t-test was 
performed in OriginPro 2017 to test the hypothesis that the means of groups were equal. Mann-
Whitney test was performed in OriginPro 2017 as a non-parametric test to test if the distributions 






Figure 4.1: Current clinical pipeline and comparison with chemical imaging pipeline. (a) 
Tissue analysis with anatomic pathology is used for diagnosis but has limited molecular 
details. (b) Surgical resections are used for staging diagnosed cancers in conjugation with 
anatomic pathology. (c) Chemical imaging with infrared spectroscopic imaging uses 
several mid-infrared frequencies of light that capture molecular details in spatially specific 
context. (d) Data acquired from infrared imaging can enable molecular assessment of the 





Figure 4.2: Spectral differences between histologic classes in the tissue and the histologic  
62 
 
(Figure 4.2 (cont.) segmentation of colon biopsy sections using supervised classification. 
(a) Average infrared spectra of the histologic classes. (b) Heat map of cluster analysis 
based on histologic classes and metrics. (c) Receiver operating characteristics (ROC) 
curves for training and validation sets show that high sensitivity (probability of detection) 
and specificity (1-probability of false alarm) for all histological classes. The color key is 
common for ROC curves and classified images. (d) Increase in error when each metric is 
permuted shows the importance of individual metrics in classification. (e) IR classified 
images show good correspondence when compared with H&E images for normal, invasive 






Figure 4.3: Risk associated features and their association with overall and disease free 
survival. (a) Schematic of feature calculation (b) Montage of high risk and low risk group 




Supplementary figure 4.1: Supervised tissue segmentation of infrared spectroscopic 
image. (a) Method pipeline. Tissue microarray is imaged with infrared imaging instrument. 
The data is processed to remove noise, correct baseline and smoothen the spectra. In 
parallel, another tissue microarray section is stained with H&E. This image is annotated 
by an expert pathologist to identify distinct areas. Annotations and infrared imaging data 
is used to train supervised classification algorithm. Here we have used Random forest 
supervised classification, which takes majority vote of a ensemble of decision trees to 
determine class label. (b) Results from analysis of variance. This figure demonstrates the 
percentage contribution of each source in variance of the spectral data, evaluated per 
metric. The metrics are ordered from highest histology contribution to the lowest. (c) 
Classifier optimization. In random forest, the two hyperparameters that are optimized are 
the leaf size and the features fed per tree. The marked circle in the plot shows the most 




Table 4.1: Univariate and multivariate cox-regression analysis of time to death based on 
risk features. The p-value corresponds to the test of null hypothesis that the beta 







 dRS 0.554 0.884 
Reactive Stroma NRS 0.006 0.095 
 MRS 0.000 0.011 
 
   
 dNS 0.843 0.734 
Normal Stroma NNS 0.360 0.474 
 MNS 0.247 0.496 
 
   
 dL 0.580 0.912 
Lymphocytes NL 0.496 0.109 
  ML 0.883 0.547 
 
Table 4.2: Multivariate cox-regression analysis of the reactive stroma risk variable MRS 
 
p Exp() 
95.0% CI for Exp() 
  Lower Upper 
MRS 0.0113 1.88211 1.1538 3.070 
Grade 0.1442 1.46061  0.8784  2.429  
Stage 7.78e-10 2.69039  1.9626  3.688  
Age 9.02e-07 1.06117 1.0363 1.087 
Sex 0.7031 1.09475 0.6874 1.744 




Table 4.3: Results of two sample t-test and Mann-Whitney test to compare values of 
continuous variable MRS across stages  
Group 
Two sample t-test  Mann-Whitney test 
p Power p 
Stage 1 vs Stage 2 0.13 0.32 0.22 
Stage 1 vs Stage 3 0.36 0.15 0.27 
Stage 1 vs Stage 4 0.23 0.22 0.21 
Stage 2 vs Stage 3 0.001 0.9 0.002 
Stage 2 vs Stage 4 0.002 0.87 0.005 
Stage 3 vs Stage 4 0.51 0.1 0.61 
Low Stage vs High 
Stage  
0.001 0.9 9.67E-04 






4.1: Spectral metrics 
used to develop 
supervised histology 
classifier. Definitions: 
1: Amide I normalized 
peak heights, where 
Col1 represents peak 
position. 2: Amide I 
normalized peak area, 
where Col1 and Col 2 
represent peak area 
bounds. 3: Peak height 





and Col2 and Col4 are 
0. Area to area ratio 
where Col1 and Col2 
represent first area 
bounds, Col3 and Col 4 
represent second area 
bound. 4: Peak centroid 
position, where Col1 
and Col2 represent area 
bounds.    
 
  
Metric Metric Definition key Col1 Col2 Col3 Col4
1 3 3113 3701 1645 0
2 3 1475 1591 1400 0
3 3 1182 1333 1448 0
4 1 1545 0 0 0
5 4 1427 1475 0 0
6 3 1182 1333 3072 0
7 3 1475 1591 1065 1186
8 3 1448 0 1400 0
9 3 1065 1186 3286 0
10 1 1664 0 0 0
11 3 1363 1427 3286 0
12 3 1065 1186 2956 0
13 3 2956 0 1120 0
14 3 1182 1333 980 1065
15 3 2947 2999 1065 1186
16 3 2852 0 1306 0
17 4 1065 1186 0 0
18 3 2947 2999 1306 0
19 3 1065 1186 980 1065
20 3 1363 1427 1448 0
21 1 1306 0 0 0
22 1 1645 0 0 0
23 3 1363 1427 3072 0
24 1 1167 0 0 0
25 3 2999 3113 1475 1591
26 4 1475 1591 0 0
27 3 2999 3113 2956 0
28 1 1448 0 0 0
29 3 1427 1475 1363 1427
30 2 1427 1475 0 0
31 3 1065 1186 1306 0
32 3 1306 0 1043 0
33 2 2947 2999 0 0
34 3 2999 3113 1591 1757
35 3 1363 1427 1545 0
36 3 2947 2999 1182 1333
37 3 1182 1333 1080 0
38 3 2885 2947 1182 1333
39 1 2956 0 0 0
40 1 1240 0 0 0
41 2 2825 2885 0 0
42 3 1363 1427 1645 0
43 3 1080 0 1043 0
44 3 1306 0 1080 0
45 3 1182 1333 1645 0
46 3 3113 3701 2947 2999
47 3 1400 0 1120 0
48 3 1591 1757 1645 0
49 3 1065 1186 1043 0
50 3 3072 0 1645 0
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CHAPTER 5: CLINICAL TRANSLATION: AUTOMATION OF BIOPSY ANALYSIS WITH 
DEEP LEARNING8 
Abstract 
Accurate, objective and automated grade diagnosis of cancer biopsies can reduce the burden on 
pathologists and speed up the clinical cancer detection and diagnosis. Infrared spectroscopic 
imaging has previously been applied for stain free tissue segmentation, but automated tissue 
analysis following tissue segmentation remains unexplored. In this study, using 148 patient 
cohort, we used infrared spectroscopic imaging assisted colon segmentation to determine the 
tumor grade. We achieved high specificity and sensitivity in tissue segmentation and grade 
classification, with 0.93 and 0.82 area under the curve (AUC) of the receiver operating 
characteristic curve (ROC) respectively. This is the first demonstration of infrared spectroscopic 
imaging based automated tissue assessment.  
Introduction 
In the United States, approximately 95,520 new colon cancer cases were estimated in 2017[1]. A 
definitive colon cancer diagnosis requires histopathological evaluation of the biopsy section by a 
pathologist. If malignancy is identified, tumor grade is determined on the basis of the percentage 
of malignant epithelium cells forming glands. Well differentiated tumors exhibit glandular 
structures in more than 95% of the tumor while poorly differentiated tumors form solid mass with 
less than 5% gland formation[277]. Tumor grade assessed in preoperative biopsies has 
prognostic value[14,278,279] and is associated with TNM stage[280,281]. Despite shown 
potential in determining patient prognosis, the clinical application of tumor grade has been limited 
due to lack of objective evaluation criteria[5,6].  
Deep neural networks based tissue segmentation and analysis is gaining traction[282] due to the 
need of automation and objective evaluation[5,6,283,284]. In colon cancer, this has been applied 
to segment colon tissue, identify nuclei from stromal and epithelial cell types[285], to characterize 
polyps[286], and to determine outcome[287]. These approaches typically utilize Hematoxylin and 
eosin (H&E) stained tissue images and the deep learning algorithms are based on morphometric 
criteria such as texture, structure and shape. When morphometry is used as a basis for primary 
tissue segmentation, additional issues are introduced. First, there is a requirement for tissue 
                                               
8 In preparation for publication as Tiwari, Saumya et al. “Clinical Translation: Automation of Biopsy Analysis with Deep Learning” 
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processing and staining. This is time consuming, and is susceptible to staining artifacts, 
experimental variation and location based variation. Second, the contrast generated by H&E 
stains is low and many tissue segments can stain identically. Infrared spectroscopic imaging can 
bypass these issues by utilizing both morphological as well as inherent biochemical differences 
in the tissue for segmentation and analysis.  
The infrared absorbance spectrum of a tissue captures the biochemical profile based on the 
absorbance of IR light by the functional groups present in the sample. In Fourier transform infrared 
(FT-IR) spectroscopic imaging, mid-infrared absorbance spectrum of each pixel of the tissue 
image is collected, thus enabling analysis of biochemical content in spatially specific manner[51]. 
Applications of FT-IR spectroscopic imaging have demonstrated high accuracy in supervised 
classification based segmentation of various tissue types, such as prostate[74], breast[288] and 
heart[186,289] and detailed reviews on the procedure, applications and methods can be found in 
the references cited herein[28,51,76,79,127,182,290].  
Following the tissue segmentation by IR spectroscopic imaging, the potential for automation of 
tissue analysis exists but has not been demonstrated so far. In this work, we aimed to enable 
automation in tissue analysis by determining the tumor grade. Using FT-IR spectroscopic imaging, 
we utilized inherent biochemical differences between tissue segments to accurately and 
reproducibly identify malignant and benign epithelium. Further, using the labelled tissue image, 
we achieved high accuracy in determining the grade of the tumor. For this, we extracted 
features[291,292] from a previously trained deep neural network AlexNet[293] to develop tumor 
grade classifier on IR histologically segmented images. With this approach, we show that a thin, 
unstained tissue slice can be imaged using infrared spectroscopic imaging and the resulting 
images can be processed through a completely automoated manner to render a final tumor grade 
assessment.  
Methods 
Data collection and segmentation 
The patient cohort used in this study to collect infrared imaging data comprised of 320 anonymous 
patients undergoing elective surgery for colorectal carcinoma. This cohort has been used 
previously[272] and described in detail in the cited reference as Cohort II. Sample preparation 
and infrared imaging of this cohort is described in the methods section in Chapter 4.  Briefly, 
paraffin embedded tissue microarrays were sectioned onto barium fluoride (BaF2) plates. These 
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sections were deparaffinized by hexane baths for 48 hours. Infrared images were collected on 
Agilent Stingray imaging system in high magnification mode with 1.1 µm pixel size at 4cm-1 
resolution. The noise in data was cleaned and baseline correction and normalization was 
performed based on previously described protocols[44,127]. The histological segmentation of the 
images annotated by our pathologist collaborator was performed with random forest supervised 
classification models and described in details in Chapter 4.  
Tumor grade determination with deep learning neural net transfer 
For training the tumor grade classifier, 20 poor grade and 50 moderate-well grade patient images 
were used. These images were stored in .jpg format and rotated 0, 90, 180 and 270 , flipped 
vertically and finally rotated 30 to expand the training set. This resulted in 16-fold expansion of 
the training set. The number of training examples corresponding to poor grade and moderate-well 
grade cases were equalized such that 320 randomly chosen moderate-well and 320 poor grade 
images were used to train the classifier. AlexNet[293], which is a deep convolutional neural 
network was used for the feature extraction task (figure 5.1a). The architecture of the network is 
described in the cited literature[293]. Since the network requires 227x227x3 images, full core IR 
based histology classified images were resized to 227x 227 pixels and saved in .jpg format.  
Network activations of second fully connected layer were used along with differentiation grade 
label (figure 5.1b) to develop support vector machine (SVM) classifier (figure 5.1c). Differentiation 
grade classifier was calibrated on an independent set from 78 patient images of which 18 were 
poor grade and 60 were moderate-well grade.  Calibration dataset was prepared in the same 
manner as the train set resulting in 288 images of poor and moderate-well categories each. 
Hyperparameters associated with SVM classifier, namely box constraint and kernel scale were 
optimized to minimize loss and prevent overfitting. Finally, for independent set, all patient images 
were used but rotated 45 to generate independent images.  
Results and discussion 
Identification of spectral regions of importance 
In developing a supervised classification model to segment colon tissue, the spectral regions 
cluster on the basis of functional differences between tissue segments.  The difference between 
these clusters can be understood in terms of the spectral regions that were most frequently 
involved in defining the metrics for these clusters (figure 5.2). A similar idea has previously been 
described as spectral barcoading, where IR spectra is used directly to identify discriminative 
71 
 
frequencies by unsupervised analysis[255]. From this analysis, the majority of fingerprint region 
between ~982-1580 cm-1 and CH stretching region between 2800-3000 cm-1 clustered together 
as C1 while OH-NH region between ~3000-3700 cm-1 and amide I region clustered together as 
C2. From the metric expression patterns of the classes in C1 and C2, it is clear that further 
association of spectral metrics exist. While 50 metrics is a good size of features to develop the 
classifier, it indicates that there is possibility of trimming down the dataset further. This can be 
done by identifying the features that are of least importance in supervised classification and 
retraining the algorithm with trimmed dataset and is demonstrated in the following section.  
Differentiation grade classifier achieves high specificity and sensitivity on independent validation 
set 
Following highly specific and sensitive tissue segment identification in infrared spectroscopic 
images of the colon, we aimed to automate diagnosis of tumor grade (figure 5.3a). For this, we 
used a machine vision based approach where a set of images is presented to the computer with 
labels, and training is performed by using specific features extracted from the image. With more 
than a million images used for training by some networks[293], deep learning based approaches 
eliminate the need to “hand draw” or manually design the features while improving classifier 
performance[294]. The features determined by deep convolutional neural networks to be optimum 
for image classification tasks are oftentimes transferable to image recognition of new objects, 
known as feature extraction[291,292]. For tumor grade classification, we utilized previously 
trained deep convolutional neural network known as AlexNet[293]. The architecture of this 
network is described in detail in the cited reference. Briefly, the deeper end of this network 
contains three fully connected layers from where features of a 3D image (227x227x3) can be 
extracted in the shape of 4096x1, 4096x1 and 1000x1 respectively. For developing the tumor 
grade classifier, we tested all three layers, and found that the second fully connected layer 
resulted in the least classification loss, leading to a feature vector of size 4096. Using these 
features, a support vector machine classifier was developed. Hyperparameters were optimized to 
determine the kernel scale value of 2.5 and box constraint value of 1e-6 (supplementary figure 
5.1). With this classifier, we achieved 0.83 training ROC AUC, 0.86 calibration ROC AUC and 
0.82 ROC AUC on an independent patient validation set comprising of 148 patient biopsy images 
(figure 5.3b). It is interesting to note that we have used full tissue microarray core images to 
perform classification instead of image patching (figure 5.3b). Upon randomizing the labels, the 
training AUC dropped to 0.43 which indicated that the performance of the classifier was label 
specific. We note that there are other permutations of classification algorithms and 
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hyperparameters that can achieve similar results.  
Finally, we predicted the tumor grade at the optimum operating point identified from the training 
ROC curve. The confusion matrices from this prediction are shown in table 5.1. For the validation 
set, we obtained 69% and 84% accuracy in classifying moderate/well grade and poor grade 
tumors respectively. There is an opportunity to improve this classification further by using a larger 
dataset and increasing the diversity of images. To adapt previously developed networks, we also 
downsampled IR classified images by approximately a factor of 5. It is possible that this 
suppresses some of the discriminatory features, and this can be tested by using image patch 
based approaches that do not require downsampling of image, but is much more computationally 
expensive. We have shown that using previously defined features can give us accurate image 
classification, and developing deep neural networks with large number of histology images could 
tailor the features further to identify histologically relevant features.  
Conclusions 
Histopathology based diagnosis is a gold standard for several diseases including cancer. There 
is an increasing burden on pathologists to perform histologic assessment, with need to perform 
time-constrained accurate assessments during surgeries. In one of the earliest work in this area, 
2047 sample set cohort was classified by 22 histopathology departments and showed statistically 
significant differences between observers, possibly arising from systematic differences in the 
techniques of assessment[5]. A recent study compared both inter and intra observer agreement 
in tumor grade determination[6]. While intra-observer agreement was substantial with Cohen’s κ 
0.704, lower inter-observer agreement was found with Fleiss’ κ 0.351. Most inter-observer 
agreement was found in classifying well differentiated cases and least inter-observer agreement 
was found in classifying moderately differentiated cases. There is a significant interobserver 
variability in assessing tumor grade. Inter-observer agreement in determining tumor grade can be 
improved by using two grade system instead of three[6], and by establishing standardized 
objective evaluation criteria[283,284]. Computational approaches could assist such assessments, 
and reduce pathologist burden by identifying areas of interest within whole slide images. 
Additionally, computational approaches can provide a means towards histopathologic 
assessment in resource-poor settings[295]. 
In this work, we showed tumor grade assessment of colon biopsy samples using infrared 
spectroscopic imaging based machine learning models. Using a large patient cohort, we 
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demonstrated the reproducibility and generalizability of our models. The use of infrared 
spectroscopic imaging offers three fold advantages in comparison to conventional approaches. 
First, due to the biochemical sensitivity of infrared spectroscopy, highly accurate tissue 
segmentation into a large number of classes can be achieved. Second, IR classified images 
provide an objective and biochemically relevant evaluation criteria for determining tumor grade. 
Third, using IR spectroscopic imaging to analyze biopsies, we eliminate the need of staining the 
tissue, staining associated errors, and preserve the tissue sample for further analysis. With the 
development of discrete frequency infrared imaging instruments[256,289], we are closer to the 






Figure 5.1: Schematic of developing deep learning based tumor grade classifier. (a) A 
pretrained ImageNet convolutional neural network, which was trained on more than a 
million images and is able to identify more than a thousand image categories was used for 
this work. Specifically, the second fully connected layer, Fc7 was used to calculate 
features from the input images. (b) Input images were obtained from supervised 
classification of colon infrared spectroscopic images. (c) Tumor grade classifier was 












Figure 5.3: Deep learning based tumor grade classification. (a) Examples of normal, well 
differentiated, moderately differentiated and poorly differentiated cases. The epithelial 
organization is increasingly disordered in higher grades. (b) Receiver operating 
characteristic curves of deep learning based tumor grade classifier show high specificity 
and sensitivity in classification. (c) Examples of IR histology classified images used to 












Table 5.1:  Confusion matrix of differentiation grade classifier. The training set had equal 
number of Moderate/Well and Poor differentiation grades. The classification decisions 
were based on the optimum operating point on the receiver operating characteristic curve, 







Moderate/Well 237/320 (74%) 83/320 (26%)
Poor 61/320 (19%) 259/320 (81%)
Classified →
Ground truth ↓
Moderate/Well 76/110 (69%) 34/110 (31%)







CHAPTER 6: CONCLUSIONS 
Summary 
Prognosis specific features are essential in the management of colorectal carcinoma. 
Morphometry based pathology is used for detection and diagnosis, but performs weakly in terms 
of prognosis, owing to large interobserver variability and lack of molecular information. In this 
work, we have developed a quantitative chemical imaging-based approach to determine patient 
prognosis. Our work presented here has three significant implications: 
• First, using infrared chemical staining, we demonstrate that patient-independent colon 
tissue segmentation can be performed without labels or dyes, providing images rapidly 
and opening the potential for in situ pathology within a human. The advancement 
presented in this work is the use of high magnification infrared imaging systems that 
provide near single cell resolution. This high spatial resolution data is coupled with 
sophisticated statistical and computational methods that ensure that patient 
heterogeneity, as well as experimental variations, are not considered while segmenting 
the tissue image. This approach consistently gave us high specificity and sensitivity when 
tested on independent samples.  
• Second, we have developed a reliable and objective method to evaluate tumor-tumor 
microenvironment interaction using quantification of infrared spectroscopic images. The 
innovation in this project is that we have developed computational models to analyze 
chemical imaging data and provide precise patient prognostic information via simple color-
coded maps without the need for human analysis. The morphometric patterns of cellular 
invasion obtained through digital histology, combined with biochemical characteristics of 
stroma in the microenvironment gives a robust prognostic marker. While we have focused 
on colorectal carcinoma in this project, this approach is widely applicable to other types of 
cancers and has the potential to provide prognostic information in cancers where 
prognosis markers are not currently available.  
• The third implication is that we have developed a novel deep learning based automation 
of the tumor grade. Using infrared chemical imaging based machine learning eliminates 
the need for tissue processing and manual examination, thus enabling rapid analysis of a 
large number of images. This development can allow early translation of infrared 
spectroscopic imaging as an advanced histopathology tool, opening up avenues for better 




Subtyping stromal cell populations 
Immune cells and stromal cells are the major cellular constituents of the tumor microenvironment, 
and each exerts an effect on the growth of the tumor. The role of lymphocytes, macrophages, 
dendritic cells, fibroblasts and endothelial cells in the modulation of biochemical and mechanical 
signals that can initiate, and help in growth and proliferation of tumor has been reviewed and 
explored before in the noted references and references therein[10,296–303]. While the biological 
effect of the cells in the tumor microenvironment is well understood, it is challenging to profile the 
changes undergone by this great variety of cells without the use of multiple probes in tissues. For 
ex-vivo tissue analysis, such as the excision biopsies, previously established analysis systems 
using genomics[304–306], proteomics[307,308], microfluidics[211] and spectroscopy[74] are 
adapted to study the cellular response in the tumor microenvironment. Chemical imaging can 
fulfill the requirement of technology for obtaining spatially specific biomolecular changes. Infrared 
spectroscopy can be used to measure early changes in fibroblasts in response to stimulation with 
cancer mimicking cellular co-culture system[158,309] which are discussed previously in chapter 
3.  Recently, proliferative and senescent fibroblast subgroups were differentiated using Raman 
and infrared spectroscopy, with changes majorly associated with degradation and storage of 
proteins and lipids, and only a small fraction of variation attributed to nucleic acids and 
carbohydrates[310]. Although many established techniques provide data without spatial 
information, our work presented here can comprehensively capture molecular changes and could 
be a critical piece in improving the systems pathology model further.   
Deep neural networks to analyze infrared spectroscopic imaging data 
Deep neural networks are characterized by a large number of hidden layers that are especially 
useful to capture complex high-level interactions between the input features[293]. Landmark 
works in analyzing infrared spectroscopic imaging data towards disease analysis have used 
simpler supervised classification models[45,74], relying on hand designing features which were 
then used for classification tasks. Such approaches are limited by spectral interpretation of the 
differences between classes and often only capture linear relationships in data. With a “large-
enough” sample size, deep neural networks could work as “end-to-end,” taking in raw data and 
learning inherent connections between the variates to perform prediction. We anticipate that with 
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the surge of high-speed infrared imaging instruments[43,45], end to end deep learning models 
will be able to take into account complex spatio-spectral features to determine prognosis.  
Multi-scale systems pathology  
Genomic revolution has provided molecular data, but we are still far from being precise in 
determining the best therapy and response of the disease. Molecular probing such as 
fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), polymerase chain reaction 
(PCR) add vital pieces of information but fail to provide the full picture. Cancer development is a 
function of genetic and microenvironmental changes. The interaction of tumor cells with its 
surrounding environment comprising of stromal cells, immune cells and stroma is continually 
evolving and adapting in response to therapies.  While most systems pathology concepts 
presented in the past have suggested integration of available data at many scales to develop a 
computational model for modeling diseases, they do not typically include tumor microenvironment 
factors in the analysis. This omission could be because our understanding of the impact of the 
tumor microenvironment on cancer progression as well as the technology to probe 
microenvironment has only developed in the past few years, much after systems pathology 
models were first explored. From the perspective of systems pathology, it is necessary to identify 
the sources of perturbations, as well as ways of quantifying these changes to be able to feed the 
data in computational models. From our work, we demonstrate that infrared spectroscopic 
imaging accurately profiles tumor microenvironment changes in the biopsies. We anticipate that 
when integrated with data obtained from genomics and proteomics, we will be able to provide a 
comprehensive systems pathology analysis of the patient.  
Personalized analysis 
Our current work enables complete automation of tissue analysis by using IR spectroscopic 
imaging to determine patient prognosis. The final step is an integration of engineering and 
medicine, opening up avenues for rapid digital histopathology and personalized tissue analysis. 
It is likely that each patient is uniquely characterized by their bio-physiological system. Thus, 
personalized prediction can be enabled by capturing complex interactions between several 
components of the system, and combining them to   perform comprehensive systems pathology. 
By incorporating patient information with spatially relevant biochemical information, there is 
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